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RIASSUNTO 
La mesotelina è una glicoproteina di superfice cellulare sintetizzata a partire da un 
precursore di 71 kDa che viene processato in un frammento di 40 kDa legato alla membrana 
ed un fattore solubile potenziante i megacariociti di 31 KDa. La mesotelina rappresenta un 
promettente biomarcatore tumorale; in condizioni fisiologiche è espressa dalle cellule 
mesoteliali delle sierose dell‘organismo (pleura, pericardio e peritoneo) mentre è 
overespressa sulla superficie cellulare di diversi istotipi tumorali tra cui: il mesotelioma 
maligno, il carcinoma ovarico, pancreatico e polmonare. La sua funzione è sconosciuta ma 
recentemente è stato ipotizzato un suo ruolo nei meccanismi di adesione cellulare attraverso 
il legame all‘antigene tumorale CA125. 
La limitata espressione della mesotelina a livello dei tessuti fisiologici e, di contro, 
l‘elevata espressione in molti tumori, rendono questo antigene un possibile target nella 
immunoterapia anti-tumorale. Il presente lavoro descrive la generazione di un nuovo 
anticorpo monoclonale anti-mesotelina ottenuto mediante la tecnologia degli ibridomi e 
la caratterizzazione delle sue proprietà di riconoscimento. Tale anticorpo monoclonale è 
stato testato per valutare un suo potenziale utilizzo terapeutico e diagnostico. 
L‘anticorpo anti-mesotelina ha dimostrato, in analisi condotte mediante citofluorimetria, 
una notevole specificità, essendo in grado di riconoscere cellule che esprimono 
l‘antigene mesotelina costitutivamente (OVCAR-3) e per trasfezione (HEK293-
mesotelina); allo stesso tempo l‘anticorpo ottenuto non possiede la capacità di legare 
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cellule mesotelina negative. La specificità di riconoscimento in vitro è paragonabile 
all‘anticorpo monoclonale commerciale K1 da noi utilizzato come controllo positivo. 
Studi di binding, inoltre, hanno permesso di evidenziare la migliore affinità del nostro 
anticorpo rispetto all‘anticorpo monoclonale commerciale K1. 
Basandoci su questi dati abbiamo sviluppato uno immunotossina chimica con le 
capacità di riconoscimento del nostro anticorpo e l‘attivita citotossica della ricina (una 
potente tossina appartenente alla famiglia delle proteine inattivanti i ribosomi) con lo 
scopo di poter utilizzare tale costrutto nella immunoterapia passiva di tumori 
overesprimenti la mesotelina. Le frazioni raccolte e purificate dell‘immunotossina, 
ottenute mediante la produzione di un ponte disolfuro tra l‘anticorpo monoclonale e la 
ricina, risultano capaci di inibire del 50% la proliferazione cellulare (IC50). Tale attività 
citotossica si manifesta su cellule mesotelina positive ad una concentrazione di 0,03 nM 
e 0,09 nM rispettivamente a 36 h e 72 h di incubazione. Inoltre il nostro costrutto 
dimostra una elevata specificità di riconoscimento in quanto non sono stati raggiunti 
valori di IC50 su cellule mesotelina-negative anche dopo aggiunta di concentrazioni pari 
o superiori a 78 nM dell‘immunotossina. Si è infine osservato che l‘attività citotossica 
di una concentrazione pari a 0,03 nM dell‘immunotossina è completamente 
neutralizzata dalla contemporanea aggiunta, nel terreno di coltura, dell‘ anticorpo anti-
mesotelina da noi generato ad una concentrazione 1000 volte maggiore rispetto a quella 
dell‘immunotossina. Questo ultimo dato supporta i precedenti ottenuti potenziando 
l‘evidenza di una attività citotossica specifica e anticorpo mediata da parte della nostra 
immunotossina chimica. 
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ABSTRACT 
BACKGROUND: Mesothelin is a tumor differentiation antigen (Ag) that is normally 
present on the mesothelial cells lining of the pleura, peritoneum and pericardium. It is, 
however, highly expressed in several human cancers including malignant mesothelioma, 
pancreatic, ovarian and lung adenocarcinoma. The normal biologic function of 
mesothelin is unknown but recent studies have shown that it binds to CA-125 and may 
play a role in the peritoneal spread of ovarian cancer. The limited mesothelin expression 
in normal tissues and high expression in many cancers makes it an attractive candidate 
for cancer immunotherapy. 
RESULTS: In this study we have developed a monoclonal antibody (mAb) that is 
specific for the Ag mesothelin. It was produced by hybridomas technologies and we 
have performed Fluorescence Activated Cell Sorting (FACS) analysis to evaluate the 
specificity and affinity of this antibody for the Ag of interest. The mAb binds 
mesothelin-positive cell lines expressing the Ag constitutively (OVCAR-3) and 
transfected cells (HEK293-mesothelin). The same mAb not recognizes mesothelin-
negative cell lines demonstrating an high specificity in vitro. Binding studies have 
demonstrated that our mAb has a better affinity with respect to mAb K1, a 
commercially available anti-mesothelin mAb.  
Our anti-mesothelin mAb was chemically linked to ricin A chain (RTA) toxin obtaining 
a powerful immunodelivered drug (immunotoxin, IT) with specific cytotoxic activity on 
mesothelin positive cells; in a cytotoxic assay on HEK293-mesothelin transfected cells 
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the anti-mesothelin mAb-RTA IT shows an IC50 of 0.03 nM and 0,09 nM after 36 hrs 
and 72 hrs of incubation respectively; no cytotoxic activity was observed against mock-
not transfected one and other mesothelin negative cells. As a further proof of specificity 
we observed that the cytotoxic activity of 0,03 nM of the above-mentionated IT on 
HEK293-mesothelin cells, is fully prevented by addition of whole molecule mesothelin-
specific antibody at a concentration 1000 fold over IT. 
CONCLUSION: Our mAb holds great potential to be used as a research reagent and 
diagnostic tool in research laboratories and in the clinics because of its high quality and 
versatility. This antibody is also a strong candidate to be investigated for further in vivo 
passive immunotherapy studies. Moreover, the discovered of this new mAb anti-
mesothelin enable us to develop in vivo diagnostic approaches using radionuclide, 
fluorescence trackers or nanoparticles. Its conjugation with therapeutic molecules allows 
a better distribution of the drug to the tumor sites; this ability increase the antitumor 
efficacy and reduce the specific toxicity at the same time. 
Introduction – Cancer Immunotherapy 
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INTRODUCTION 
Cancer malignancies are among the most life-threatening diseases in industrialized 
countries. Although established cancer therapies, including surgical resection of the 
primary tumor, radiation and chemotherapy, are well established, cancer still causes 
25% of mortalities. Annually, about 1% of the population that has been diagnosed with 
cancer, die. Five-year survival rates range from 10-20% for lung, esophagus and 
stomach cancer, to 40-60% for colon, bladder and cervix cancer, and 60-80% for breast 
and prostate cancer (www.rex.nci.nih.gov). Whereas the primary tumor can in most 
cases be treated efficiently by a combination of standard therapies, preventing the 
metastatic spread of the disease through disseminated tumor cells is currently 
ineffective. 
THE CANCER PROBLEM FROM AN IMMUNE SYSTEM PERSPECTIVE 
Cancer immunotherapy – as an alternative modality of treatment – has significantly 
developed during the last decades and completes the therapeutic arsenal. In contrast to 
the other therapeutic concepts, immunotherapy primarily aims to prevent metastatic 
spread of the disease and to improve quality of life of the affected individuals. 
Approaches that are applied in immunotherapy are based on complementation or 
stimulation of the immune system via a plethora of compounds, such as lymphokines, 
vaccines, in vitro-stimulated effector cells of the immune system or antibodies. Immune 
surveillance is the concept that envisages prevention of the development of tumors by 
Introduction – Cancer Immunotherapy 
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the early destruction of abnormal cells by the immune system of the host. Consequently, 
a lack of (or escape from) immune surveillance plays an essential role in cancer 
development, and may be associated with an evasion of tumor cells from the 
surveillance of the immune system, which in particular seems to be an escape from 
specific T-cell mediated immunity [1-2]. Due to their genetic instability, tumor cells 
usually express abnormal proteins, i.e., tumor-associated antigens (TAAs), which have 
no or very limited expression on normal cells [3-4]. Such TAAs expose new, potentially 
immunogenic epitopes, which can be recognized by the immune system of the host 
(Figure 1). 
 
Fig. 1 Tumor-associated surface changes. 
Interestingly, the endogenous immune response against these epitopes has only a 
marginal effect on the tumor [5]. With progression of tumor growth, the cytotoxic 
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immune response at the tumor site has been found to be inhibited, and invading T cells 
and antigen-presenting cells (APCs) often appear to be non-functional [6-7]. Moreover, 
tumor themselves have been shown to down-regulate the immune surveillance by 
secreting immunosuppressant factors like interleukin IL-10 or transforming growth 
factor-β [8-9]. 
Active Cancer Immunotherapy: 
cancer immunotherapy is intended to restore reactivity of the host‘s immune system to 
combact cancer. Active cancer immunotherapy aims at induction of an endogenous, 
long-lasting tumor antigen-specific immune (preventive or therapeutic) response [10] 
(Figure 2). For this specific vaccination approach defined TAAs or material obtained 
after biopsy of the tumor is used [3-4]. The immune response against the tumor can be 
further enhanced by unspecific stimulation of the immune system using stimulators such 
as adjuvants or so-called biological response modifiers (e.g. cytokines). An alternative 
to the induction of an immune response in vivo (by administration of a tumor antigen as 
a vaccine to the host‘s APCs) is ex vivo stimulation of autologous dendritic cells (DCs) 
with re-application of the DCs to the patient, as a method to break the patient‘s immune 
tolerance for TAAs. 
Passive Cancer Immunotherapy: 
passive cancer immunotherapy, on the other hand, provides a tumor antigen-specific 
immune response by supplying high amounts of effector molecules, i.e., tumor-specific 
antibodies or effector cells, i.e., cytotoxic T lymphocytes. In contrast to active 
Introduction – Cancer Immunotherapy 
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immunization, passive cancer immunotherapy is short lived, and dependent on repeated 
applications [10]. Antibodies as part of the humoral immune system recognize antigenic 
structures, neutralize them or mediate effector functions like antibody-dependent 
cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC) (Figure 
2). Cancer immunotherapy should take into account the genetic instability of the tumor 
cells, as they rapidly adapt to changes in their environment. Monovalent therapies 
targeting only one epitope may, therefore, not provide long-term protection because 
tumor cells may escape immune surveillance by down-regulating the targeted antigen 
[1]. Multi-epitope targeting approaches could strongly reduce evasive cancer potential, 
and may eventually prevent tumor escape [11]. 
 
Introduction – Cancer Immunotherapy 
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Fig. 2 Cancer Immunotherapy. The whole spectrum of passive and active cancer immunotherapy is 
summarized. Active cancer immunotherapy comprises tumor antigen uptake by APCs (1), epitope 
(peptide) presentation to CD4+ T cells (2), cytokine release (3), B cell activation (4), and antibody 
production (5), leading to lysis of tumor cells including different (passive) alternatives like ADCC (6), 
CDC (7) or unspecific attack by cytotoxic T limphocytes (8) (Schuster M., et al., 2006). 
MONOCLONAL ANTIBODIES: VERSATILE PLATFORMS FOR CANCER 
IMMUNOTHERAPY AND DIAGNOSTIC APPLICATIONS 
Antibodies are grouped into five classes based on the sequence of their heavy chain 
constant regions: IgM, IgD, IgG, IgE and IgA. Of the five classes, IgG is the most 
frequently used for cancer immunotherapy. Antibodies can be subdivided into two 
distinct functional units: the fragment of antigen binding (Fab) and the constant 
fragment (Fc). The Fab contains the variable region, which consists of three 
Introduction – Cancer Immunotherapy 
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hypervariable complementarity-determining regions (CDRs) that form the antigen 
binding site of the antibody and confer antigen specificity. Antibodies are linked to 
immune effector functions by the Fc fragment, which is capable of initiating CDC, 
binding to Fc receptors for IgG (FcγRs) and binding to the neonatal FcR (FcRn) [12]. 
The concept of using antibodies to selectively target tumors was proposed by Paul 
Ehrlich over a century ago [13]. The advent of hybridoma technology in 1975 enabled 
the production of monoclonal antibodies [14]. Owing to their origins in mice, these 
monoclonal antibodies were typically immunogenic in humans and had poor abilities to 
induce human immune effector responses, thereby limiting their clinical applicability. 
Later advances in antibody engineering provided flexible platforms for the development 
of chimeric, humanized and fully human monoclonal antibodies which satisfactorily 
addressed many of these problems (see Timeline). 
 
Fig. 3 TIMELINE Box outline: blue, chimeric antibody; red, humanized antibody; yellow, human 
antibody; green, mouse antibody (Louis M. Weiner, et al., 2010). 
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Murine monoclonal antibodies: 
these antibodies are derived entirely from mice using hybridoma technology, which 
involves the fusion of immortalized myeloma cells with B-cells from immunized mice. 
In humans, these antibodies often had limited clinical utility because they have short 
circulating half-lives [15], are immunogenic [16-17] and have difficulties inducing 
human immune effector responses [18]. Their main use has been to serve as targeting 
agents for radioisotopes or cytotoxins that kill targeted tumor cells. To date, two 
radiolabelled murine antibodies, ibritumomab tiuxetan and tositumomab, have been 
approved for use in cancer therapy (Table 1) [19]. 
Chimeric and humanized monoclonal antibodies: 
the desire to reduce the immunogenicity and to increase the immunologic efficiency of 
antibodies led to the production of chimeric and humanized mAbs [20–21]. Chimeric 
mAbs are constructed by fusing the murine variable regions onto human constant 
regions. Humanized mAbs were constructed by grafting murine antigen binding regions 
(CDRs) onto human antibodies. Unfortunately, humanized mAbs often have 
considerably poorer affinity than the parent murine mAb and require further 
manipulation (typically by introducing mutations in the CDRs) to restore the affinity 
and specificity of the original murine mAb [22]. The majority of approved anticancer 
mAbs are humanized antibodies (Table 1). 
Introduction – Cancer Immunotherapy 
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Fully human monoclonal antibodies: 
the immunogenicity of therapeutic mAbs affects their efficacy and safety. Patient 
immune responses raised against the therapeutic mAbs can neutralize their action, 
whereas hypersensitivity to these mAbs can result in morbidity and mortality. Fully 
human mAbs were developed to further reduce immunogenicity associated with 
chimeric or humanized mAbs, both of which still retain some murine components [23-
24]. Human mAbs have been produced using either transgenic mice (transgenic animals 
bearing a ‗human‘ immune system) or phage display technology [25]. Elimination of the 
murine protein sequences has generally been found to reduce the frequency of mAb-
targeted immune responses and hypersensitivity reactions [26]. Panitumumab and 
ofatumumab are two human mAbs that have been approved for use in the clinic (Table 
1). Both these mAbs were produced by transgenic mice technology. Panitumumab was 
produced with the Abgenix Xeno-Mouse technology and ofatumumab was generated 
from the UltiMab platform [23]. 
Recombinant antibody constructs: 
several recombinant antibody constructs have been produced to increase affinity, 
improve penetration and retention by solid tumors, mediate enhanced human immune 
effector responses and demonstrate favourable plasma pharmacokinetics. The targeting 
specificity of whole mAbs can be retained in these recombinant constructs. Another 
advantage is that these constructs can often be produced at lower cost [27]. Examples of 
such constructs include single chain-variable fragments (scFvs), multivalent scFvs (e.g. 
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diabodies and tribodies), minibodies (e.g. scFv-CH3 dimers), bispecific antibodies, Fab 
and Fab´2 fragments and camel variable functional heavy chain domains (see reviews by 
Beckman et al. [28] and Hudson [29]). No such construct has yet been approved for use 
in humans.  
MECHANISM OF ACTION OF THERAPEUTIC MONOCLONAL 
ANTIBODIES 
Immune system activation: 
antibodies are thought to function through several different mechanisms, although 
antibody-dependent cell cytotoxicity (ADCC) and complement-dependent cytotoxicity 
(CDC) are thought to be particularly important. ADCC involves destruction of the 
antibody-coated cell by recruitment of effector cells (such as natural killer cells, 
macrophages and neutrophils) whereas CDC involves destruction through complement 
activation. Both ADCC and CDC are mediated via the Fc region of the antibody, with 
mAbs of the IgG1 isotype being most effective at inducing ADCC and CDC [12-19-30-
31]. FDA approved mAbs that are believed to use ADCC as their primary mode of 
action are rituximab and ofatumumab; however their activity is also thought to partially 
depend on CDC. By contrast, alemtuzumab induces CDC but not ADCC [17]. Certain 
mAbs that primarily function by disrupting signalling pathways have also been shown 
to induce ADCC (Table 1). ADCC occurs when antibodies bind to antigens on tumor 
cells and the Fc portion of the mAb engages Fcγ receptors (FcγRs) on the surface of 
immune effector cells. A seminal paper by Ravetch and colleagues (Nature 
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Immunology, 2010) demonstrated the importance of Fc-FcγR interactions for the in vivo 
antitumor effects of trastuzumab and rituximab. This study showed that the antitumor 
activities of these mAbs were lower in FcγR-deficient mice than in wild-type mice [25]. 
The importance of the FcγR in the antitumor response of therapeutic mAbs has been 
further supported by the discovery that polymorphisms in the genes encoding FcγRs, 
that lead to a higher affinity of mAbs for the FcγR, are associated with higher clinical 
response rates in patients. Polymorphisms in the FcγR genes have been shown to be 
associated with clinical responses to rituximab, trastuzumab and cetuximab [32-33-34]. 
The ability of therapeutic mAbs to mediate ADCC is also influenced by its 
oligosaccharide content. The majority of currently used mAbs are highly fucosylated 
because of the nature of the cell lines used for their production. Generation of mAbs 
with defucosylated oligosaccharides has been shown to enhance ADCC in vitro and 
enhance antitumor activity in vivo [17-23]. Tumors can escape the immune system by 
inducing regulatory T cells which function to suppress the patient‘s immune responses. 
Specific antigens expressed on the surface of these regulatory T cells which are 
involved in immunosuppression, such as cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4), are therefore attractive targets for therapeutic mAbs. Such 
immunomodulation might allow for a more effective immune response to the tumor. 
Ipilimumab and tremelimumab are two anti-CTLA-4 blocking mAbs that have been 
studied in clinical trials and shown to induce delayed disease regression in patients with 
metastatic melanoma [24]. 
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Table 1 Since 1997, ten mAbs have received approval from the United States Food and Drug 
Administration (US FDA) for the treatment of a variety of solid tumours and haematological 
malignancies, and a large number of additional therapeutic antibodies are currently being tested in early 
and late stage clinical trials (http://www.clinicaltrials.gov) (Vinochani Pillay et al., 2011). 
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Blockade of ligand binding and signaling perturbation: 
Increased expression of growth factor receptors during tumorigenesis also make them 
attractive targets for therapeutic antibodies (Table 1). mAbs can exert antitumor effects 
by blocking ligand binding to growth factor receptors and inhibiting signaling through 
these receptors, thereby inhibiting proliferation of the targeted cells, inducing apoptosis 
and/or sensitizing tumors to chemotherapeutic agents [19-32]. Two approved mAbs, 
cetuximab and panitumumab, are believed to function primarily by binding to and 
blocking epidermal growth factor receptor (EGFR, also called ErbB1) mediated 
signaling. Because EGFR enhances both tumor cell proliferation and neoangiogenesis, 
inhibition of this signalling pathway reduces cell proliferation and tumor angiogenesis. 
Inhibition of EGFR signalling also sensitizes the cells to chemotherapy and radiation 
[35]. HER2 (or ErbB2) belongs to the same family as EGFR but has a truncated 
extracellular domain that is unable to bind ligand. Antibodies targeting this receptor 
function mainly by inhibiting receptor homo and hetero-dimerization and internalization 
rather than preventing ligand binding [36-37]. Trastuzumab, which is used for the 
treatment of metastatic breast cancer, selectively inhibits HER2 homodimer-induced 
tyrosine kinase activation, whereas pertuzumab blocks HER2 dimerization with any 
ErbB receptor [38]. An approved antibody, bevacizumab, blocks binding of vascular 
endothelial growth factor (VEGF) to its receptor and inhibits tumor angiogenesis [39–
40]. Two other growth factor receptors that have received some interest as potential 
targets for mAb therapy are the receptor tyrosine kinases c-MET and insulin-like growth 
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factor receptor 1 (IGFR1). mAbs targeting c-MET and IGFR1 are currently under 
clinical development (http://www.clinicaltrials.gov). 
Conjugates: 
despite these advances, there are still limitations to mAb therapeutics, including poor 
penetration into tumors, with only a small percentage of the administered mAb 
localizing within the tumor, and slow extravasation of the drug from the blood supply 
[41-42]. Additionally, antibodies are expensive to generate, which increases the costs of 
the marketed drugs [43-44]. Monoclonal antibody therapies are often not curative and 
may need to be combined with chemotherapy [45]. As a result, there has been 
tremendous interest in finding a way to increase the therapeutic effectiveness of the 
mAb through attachment to a toxin, drugs, or radionuclides. Antibody drug conjugates 
(ADCs) consist of an antibody attached to a cytotoxic drug by means of a linker (Figure 
4). ADCs provide a way to couple the specificity of a monoclonal antibody (mAb) to 
the cytotoxicity of a small molecule drug and, therefore, are promising new therapies for 
cancer. ADCs are prodrugs that are inactive in circulation but exert their cytotoxicity 
upon binding to the target cancer cell. 
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Fig. 4 Schematic of an ADC. The schematic for the structure of an ADC is shown along with examples of 
antibodies, linkers and drugs used to make some of the ADCs currently in clinical trials (Iyer U., et al., 
2011). 
 
Yttrium-90 (Y-90) and iodine-131 (I-131) are two of the most common isotopes 
conjugated to mAbs in the clinic [19]. Two radiolabelled murine mAbs, namely Y-90 
ibritumomab tiuxetan and I-131 tositumomab, have been approved for Non-Hodgkin‘s 
Lymphoma (NHL, Table 1). Calicheamicin is a highly potent toxin that binds to DNA, 
causing double-strand breaks and cell death by apoptosis. Gemtuzumab ozogamicin is a 
calicheamicin immunoconjugate targeted to CD33 that has been approved for the 
treatment of acute myeloid leukaemia (AML) (Table 1). Examples of other 
calicheamicin conjugates that have been evaluated in the clinic include CMB-401 and 
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CMD-193, where the calicheamicin is conjugated to the anti-MUC1 antibody CTM01 
[46] or the anti-Lewis Y antibody hu3S193 [47-48], respectively. Other toxins that have 
received recent attention for development of immunoconjugates include maytansinoids, 
ricin A and Pseudomonas exotoxin A [35]. Maytansinoids are a naturally occurring 
group of highly potent cytotoxic agents that exert their antitumour activity by binding to 
tubulin, and inhibiting microtubule assembly and cell division. Trastuzumab-DM1 is a 
novel maytansanoid antibody-drug conjugate that has shown promising efficacy as first-
line therapy in patients with HER2 (human epidermal growth factor receptor 2) - 
positive metastatic breast cancer in a recent Phase II clinical trial [35-49]. Brentuximab 
vedotin (SGN-35) is an immunoconjugate consisting of an anti-CD30 antibody and 
monomethyl auristatin E, an antimitotic agent which inhibits cell division by blocking 
the polymerization of tubulin. A recently published Phase I trial showed that 
brentuximab vedotin provided a high response rate in patients with relapsed or 
refractory CD30-positive lymphomas [50]. Figure 5 shows the sequence of events that 
occur upon binding of the ADC to the target antigen. 
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Fig. 5 Mechanism of Action of ADCs. The ADC is internalized by receptor-mediated endocytosis and 
cleavage of the linker occurs within the cell to release the cytotoxin, which then targets either the DNA or 
the microtubules to kill the cell (Iyer U., et al., 2011). 
 
Careful selection of the different components of the ADC is critical to successful design 
of ADCs that could be used as cancer therapeutics. Apart from optimizing the 
component parts, efforts to build better ADCs have led to much research into all the 
characteristics of the ADC that may affect its therapeutic index, including conjugation 
of the antibody to the linker and the drug, drug-antibody ratios, and the mechanism by 
which ADCs effect cell killing.  
DIAGNOSTIC APPLICATION OF ANTIBODIES 
Conventional tumor imaging approaches such as CT (contrast-enhanced helical) and 
MRI (magnetic resonance imaging) mainly focus on delineating morphological features 
of the tumor such as anatomic location, extent, and size. Despite continuous 
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improvements in spatial resolution with advanced imaging equipment, imaging 
modalities using non-targeted contrast agents, such as CT and MRI, have limited 
sensitivity and ability to provide specific and functional informations on the disease, 
which is increasingly recognized to be an obstacle to earlier diagnosis and the 
monitoring of treatment responses. Recent advances have stimulated the emergence of 
the new field of ―molecular imaging,‖ which focuses on visualizing or imaging 
biological events and processes in living systems, including patients. Current molecular 
imaging approaches include scintigraphy/immuno-scintigraphy, PET/immuno-PET and 
optical imaging including fluorescence-mediated tomography and near-infrared 
fluorescence reflectance (NIRF) imaging.  
The development of antibodies for molecular imaging has been promoted by the 
development of engineered fragments with pharmacokinetics optimized for imaging. 
Reduction of the overall size of antibody-based fragments can result in accelerated 
blood clearance due to removal of the Fc region and by reduction of the molecular 
weight to a size below the threshhold for first-pass renal clearance. scFvs represent 
convenient modules for engineering antibody-based fragments that retain full binding 
specificity (i.e. diabodies, triabodies, tetrabodies, tandem diabodies and minibodies 
derived from the fusion of scFvs to the antibody CH3 domain) but also exhibit a suitable 
range of format dependent blood-clearance properties. Successful imaging requires that 
the tracer must circulate long enough to allow sufficient perfusion and binding in target 
tissues, coupled with reasonably fast clearance from the circulation. Diabodies, for 
example, exhibit terminal half-lives in the range of 3–5 h and can reach levels of 7%-
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10% injected dose per gram in tumor xenograft models. Bivalent minibodies above the 
threshhold for renal clearance exhibit intermediate kinetics and allow higher overall 
uptake levels (20% injected dose/g) in target tissues. 
Radioimmunoscintigraphy 
Radioimmunoscintigraphy (RIS) involves the administration of radiolabeled 
monoclonal antibodies (mAbs) directed against specific molecular targets, followed by 
imaging with an external gamma camera. MAbs that react with specific cellular antigens 
are conjugated with a radiolabeled isotope. The labeled antibody-isotope conjugate is 
then injected into the patient and allowed to localize to the target over a 2-7 days period. 
The patient then undergoes imaging with a nuclear medicine gamma camera and 
radioisotope counts are analyzed. Imaging can be performed with planar techniques or 
by using single photon emission computed tomography (SPECT).  
To date FDA-approved monoclonal antibody radiopharmaceuticals include (2009 
CPT/HCPCS revisions): 
- 
111
I-satumomab pendetide (CYT-103, OncoScint CR/OV) has been FDA approved for 
imaging of colorectal and ovarian carcinoma; 
- 
99
Tc-nofetumomab merpentan (Verluma) is FDA approved for the detection of 
extensive stage disease in patients with biopsy confirmed, previously untreated small 
cell lung cancer patients; 
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- 
99
Tc- arcitumomab (IMMU-4, CEA-Scan) has been FDA approved for use in 
colorectal and ovarian carcinoma; 
- 
111
I-pentetreotide (Octreoscan) has been FDA approved for use in scintigraphic 
localization of primary and metastatic neuroendocrine tumors bearing somatostatin 
receptors, typically pancreatic islet cell tumors or adrenals ones; 
- 
111
I-capromab pendetide (Prostascint) has been FDA approved for imaging of pelvic 
lymph nodes in patients with newly diagnosed, biopsy proven prostate cancers or in 
post-prostatectomy patients in whom there is an high clinical suspicion of occult 
metastatic disease. ProstaScint consists of an intact murine monoclonal antibody, 7E11-
C5.3, to which a linker chelator (GYK-DTPA-HCL) is bound, labeled with 
111
In. The 
overall sensitivity and specificity of detecting disease using capromab pendetide has 
varied in reported studies. These studies demonstrated average sensitivities of 60%, 
specificities of 70%, positive predictive values of 60%, and negative predictive values 
of 70%. In a meta analysis, 
111
In-labeled capromab pendetide studies in 2,154 patients 
from 15 institutions were analyzed. The overall sensitivity for detection of tumor in 
biopsy-proven primary carcinoma was 80%. The sensitivities ranged from 75% to 99% 
because of significant inter-reader variability. Antibody imaging is limited by its ability 
to detect viable disease. This may be related to the fact that the antibody binds to the 
intracellular part of PSMA and hence detects only necrotic tissue. J591, an antibody that 
detects the extracellular domain of PSMA, has been studied. These studies have 
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demonstrated antibody localization to known disease. However, this antibody has not 
been extensively studied as an imaging agent. [51-52-53-54]. 
Immuno-PET 
Successful implementation of immuno-PET requires an appropriate match between the 
physical half-life of the positron-emitting radionuclides and biologic half-life of the 
antibody. PET radionuclides with half-lives in the order of days would be ideally suited 
for conjugation with intact antibodies for clinical imaging; recent examples are 
represented by 
89
Zr (78.4 h) and 
124
I (100.2 h). The clinical utility of 
89
Zr-labeled U36, a 
chimeric antibody specific for CD44v6, has been demonstrated in a series of 20 patients 
with head and neck cancer. All of the primary tumors and 72% of the lymph node 
pathologist-confirmed metastases were detected in this clinical immuno-PET study. 
Similarly immuno-PET imaging, with 
124
I-labeled cG250, an antibody directed against 
anticarbonic anhydrase-IX, resulted in successful detection of 15 of 16 clear-cell 
carcinomas. In these pre surgical studies, the final immuno-PET scans were acquired 6–
8 days after injection, just before surgery. In order to further improve quality and 
specificity of PET-imaging other strategies are under study; pre targeting approaches in 
particular represent the new frontier also for imaging applications. Antibody loading of 
antigenic sites followed by radionuclide hapten delivery could allow higher tumor/blood 
localization ratio, lowering side effects due to longer half-life of pre-constituted 
antibody radionuclides complexes. One of the most promising developments, with 
implications for clinical translation, is the demonstration of rapid 
18
F labeling and 
imaging of colon carcinoma xenografts pretargeted with an anti-CEA diabody. The 
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antigen-positive tumor was readily detected by small-animal PET imaging at time points 
from 1 to 6 h after injection [55]. 
Besides antibody and radionuclide features, development of immuno-PET strategies has 
also to face antigen characteristics such as internalization and normal vs tumor tissue 
expression. Selection of the appropriate receptor or antigen on cancer cells is crucial for 
the optimal design of targeted imaging approach. The ideal targets are those that are 
abundantly and uniquely expressed on tumor cells, but have negligible or low 
expression on normal cells. The targeted antigen should also have a high density on the 
surface of the target tumor cells. Whether the conjugates are prone to be internalized 
after binding to the target cell is another important criterion which addresses the choice 
of proper targeting strategy. In the context of pre-targeting RIT strategies, targeting 
internalizable antigens implies that the antibody-antigen complex is no longer available 
for subsequent tracer binding; this fact render internalizing antigens unsuitable for 
multisptep pretargeting approaches unless residualizing radiolabel measures are 
adopted. Conjugates directed against internalizing antigens, once internalized, are also 
addressed to intracellular processing which often lead to separation of vehicle from 
tracer [56]. 
Furthermore many targets that are suitable for therapeutic applications, such as 
epidermal growth factor receptor, are not likewise imaginable because of normal tissue 
expression.
Introduction – Mesothelin Targeted Cancer Immunotherapy 
34 
 
Mesothelin is a differentiation antigen whose expression in normal human tissues is 
limited to mesothelial cells lining the pleura, pericardium and peritoneum [57-58]. 
However, mesothelin is highly expressed in several human cancers, including virtually 
all mesotheliomas and pancreatic adenocarcinomas, and approximately 70% of ovarian 
cancers and 50% of lung adenocarcinomas [59-62] (Table 2). The mesothelin gene 
encodes a precursor protein of 71 kDa that is processed to a 31 kDa shed protein 
called megakaryocyte potentiating factor (MPF) and a 40 kDa fragment, mesothelin, 
that is attached to the cell membrane by a glycosyl- phosphatidylinositol (GPI) anchor 
[57-63] (Figure 6). 
Table 2: Mesothelin expression in human cancers 
a
  
TUMOR MESOTHELIN 
EXPRESSION (%) 
COMMENTS REFERENCE 
Mesothelioma 100 Present in all epithelial mesotheliomas but 
absent in sarcoma type 
59,64 
Pancreatic cancer 100 Absent in normal pancreas and chronic 
pancreatis 
60,62,70 
Ovarian cancer 67-100 Mostly in serous ovarian adenocarcinomas 
although it is also expressed to a lesser 
degreee in other sub- types 
58,61,62,68 
Lung 
adenocarcinoma 
41-53 Some expression in squamous and large 
cell lung cancer but absent in small cell 
lung cancer 
62,69 
a Detected by immunohistochemestry (Hassan R., et al., 2008).
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MESOTHELIN EXPRESSION IN HUMAN CANCERS  
Mesothelin gene expression in human cancers has been studied using serial analysis of 
gene expression (SAGE) tag analysis (http://www.ncbi.nlm.nih.gov/projects/SAGE/). 
High mRNA expression of mesothelin is found in mesothelioma, lung, ovarian and 
pancreatic adenocarcinomas. In addition, immunohistochemistry (IHC) has helped 
delineate the frequency and pattern of mesothelin protein expression in these tumors 
(Figure 7). These studies have been greatly facilitated by the commercial availability of 
             
Fig. 6 Schematic of mesothelin. The human mesothelin (MSLN) gene encodes a precursor 
protein of 622 amino acids. On translocation into the endoplasmic reticulum (ER) the N - 
terminal signal peptide (red; residues 1–33) and the C - terminal glycosyl-phosphatidylinositol 
(GPI) anchor addition signal (blue; a predicted cleavage site: Ser598) are removed and the 
latter replaced with a GPI anchor. The MSLN precursor is cleaved into two products, mature 
megakaryocyte potentiating factor (MPF; residues Ser34– Arg286) and the GPI-anchored 
membrane-bound mature MSLN (orange) starting from Glu296. The proteolytic cleavage region 
(green) contains a furin cleavage site at Arg295, and other protease cleavage sites including a 
trypsin cleavage site at Arg286. The four N-linked glycans (black lollipops; Asn57, Asn388, 
Asn488 and Asn515) are indicated (Hassan R., et al., 2008). 
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monoclonal antibody (mAb) 5B2 (Novocastra, Newcastle-on Type, UK) that can detect 
mesothelin expression in paraffin embedded tissues. 
 
Fig 7 Mesothelin expression in human tumours. Mesothelin expression was detected by IHC using 
monoclonal antibody (mAb) 5B2 in tissue specimens of patients with mesothelioma (A); ovarian cancer 
(B); pancreatic adenocarcinoma (C) and lung adenocarcinoma (D) (Hassan R., et al., 2008). 
 
Mesothelioma 
Mesothelin is highly expressed in epithelial malignant mesothelioma. In the original 
study by Chang and colleagues, mesothelin expression was evaluated by mAb-K1 using 
frozen section tissues of patients with malignant mesothelioma [64]. Out of the 23 
pleural mesothelioma samples analysed all 15 epithelial mesothelioma samples had 
mesothelin expression, while 4 sarcomatous mesotheliomas were negative. In the four 
samples with biphasic mesothelioma, only the epithelial component stained for 
mesothelin. Mesothelin expression in paraffin embedded mesothelioma tissue samples 
was studied by Ordonez using mAb 5B2 [59]. Out of the 55 mesothelioma specimens 
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(44 epithelioid, 3 biphasic and 8 sarcomatoid) studied mesothelin reactivity was noted 
in all epithelioid mesotheliomas and the epithelial component of biphasic 
mesotheliomas. However, none of the sarcomatous mesotheliomas expressed 
mesothelin. These results are in agreement with the results of Chang and colleagues that 
mesothelin is present in all epithelial mesotheliomas and is absent in the sarcomatous 
type. Although mesothelin is not a specific marker for mesothelioma a negative 
mesothelin immunostain strongly argues against the diagnosis of epithelioid 
mesothelioma [65]. 
Pancreatic cancer 
Argani and colleagues were the first to show mesothelin expression in pancreatic ductal 
adenocarcinoma [60]. Using SAGE database they found the tag for mesothelin to be 
consistently present in pancreatic cancer libraries but not in normal pancreas. In 
addition, mesothelin mRNA expression was present in 4 of 4 resected primary 
pancreatic cancers and by immunohistochemistry all 60 resected primary 
adenocarcinomas were mesothelin positive. These results were confirmed by Hassan 
and colleagues who showed that mesothelin was expressed in all 18 cases of pancreatic 
adenocarcinomas examined but absent in normal pancreas and in chronic pancreatitis 
[66]. Ordanez also showed mesothelin was expressed in majority of pancreatic 
adenocarcinomas, but was absent in islet cell tumors of the pancreas [62]. In addition to 
pancreas mesothelin is also highly expressed in other adenocarcinomas of the biliary 
tree such as gallbladder cancer, and tumors of the common bile duct [66-67]. 
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Ovarian cancer 
Using mAb-K1 Chang and colleagues demonstrated mesothelin expression in 10 out of 
15 non-mucinous epithelial ovarian carcinomas while as it was absent in all 4 mucinous 
ovarian cancers examined [58]. Using 5B2 anti-mesothelin antibody Ordanez noted 
mesothelin expression in 14 of 14 serous, 3 of 3 endometrioid, 6 of 8 clear cell and 3 of 
6 mucinous ovarian carcinomas [62]. Using tissue microarrays containing ovarian 
cancer specimens Frierson and colleagues showed that all 38 serous ovarian cancers 
expressed mesothelin while only 1 of 8 mucinous ovarian tumor had mild mesothelin 
expression [68]. In contrast to the studies of Ordanez and Frierson and colleagues who 
noted mesothelin expression in 100% of serous ovarian cancer, Hassan and colleagues 
noted mesothelin expression in 27 of 33 (82%) of serous ovarian cancers [61]. Based on 
these results one can conclude that mesothelin expression is present in most serous 
ovarian cancers, which constitute the majority of epithelial ovarian cancers, but is also 
expressed to a lesser degree in other subtypes of ovarian cancer. 
Lung cancer 
Though earlier studies using mAb-K1 showed no expression of mesothelin in lung 
adenocarcinomas, several recent studies using the 5B2 anti-mesothelin mAb show high 
expression in these tumors [64]. In the study by Ordonez looking at mesothelin 
expression in different human cancers, mesothelin expression was present in 14 of 34 
(41%) lung adenocarcinomas [62]. This was confirmed in a large study by Miettinen 
and Sarlomo-Rikala who evaluated mesothelin expression in 596 lung carcinomas [73]. 
In this study, mesothelin expression was present in 78 of 148 (53%) adenocarcinomas, 
15 of 118 (13%) large cell carcinomas, 29 of 124 (23%) squamous cell carcinomas and 
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0 of 41 (0%) small cell lung cancers. One unusual feature of the lung cancer is that there 
is more intracellular mesothelin reactivity than seen in mesotheliomas, ovarian or 
pancreatic cancer where the mesothelin staining is predominantly at the cell surface or 
normal mesothelial cells. Studies by Ho and colleagues have further delineated 
mesothelin expression in human lung cancer [70]. Using NCI-60 cell line panel they 
detected mesothelin mRNA in 7 of 9 (78%) lung cancer cell lines. In 4 of the 7 cell lines 
in which mesothelin mRNA was detected, cell surface mesothelin expression was 
detected by flow cytometry. In addition, mesothelin mRNA was present in 10 of 12 
(83%) lung adenocarcinomas samples obtained from patients. These results support 
earlier studies by Ordanez and Miettinen that show mesothelin expression by 
immunohistochemistry in about half the patients with lung adenocarcinoma. 
Mesothelin expression in other human tumors 
In addition to the above tumors mesothelin over-expression has been noted in some 
other human cancers. It is commonly expressed in squamous cell carcinomas of 
different sites such as cervix, lung and head and neck carcinomas as well as endometrial 
adenocarcinomas [62-71-72]. Mesothelin expression by immunohistochemistry is 
infrequently present in colorectal, gastric and esophageal cancers [62]. Mesothelin 
expression is absent in soft tissue sarcomas with the notable exception of biphasic 
synovial sarcomas [62]. Cancer with absent mesothelin expression include melanomas, 
renal cell cancer, transitional cell carcinomas, thyroid cancer, breast cancer, prostate 
cancer and germ cell tumors [62]. 
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MESOTHELIN BIOLOGY  
The normal biologic function of mesothelin is not clear. Bera and colleagues generated 
mutant mice in which the mesothelin gene was inactivated, and neither mesothelin 
mRNA or protein was detected in the homozygous mutant mice [73]. These mesothelin 
knockout mice did not have a detectable phenotype and both males and females 
produced offspring normally. These results suggest that in mice mesothelin function is 
not essential for growth or reproduction. Although the functions of mesothelin remain 
largely unknown, recent studies have shed light on the possible role of mesothelin in 
cancer biology. 
Mesothelin binding to MUC16/CA-125 and ovarian cancer  
MUC16/CA125 is a very large cell surface mucin, with an average molecular weight 
between 2.5 and 5 million dalton, that is also heavily glycosylated with both O-linked 
and N-linked oligosaccharides [74]. It is shed into the serum and is used for monitoring 
response to therapy in ovarian cancer [75]. Rump and colleagues were the first to show 
that binding of CA-125 to membrane bound mesothelin mediates heterotypic cell 
adhesion since an anti-mesothelin antibody blocks this interaction [65]. Their results 
suggest that mesothelin is a novel CA-125 binding protein and that CA-125 might lead 
to intraperitoneal dissemination of ovarian carcinoma by binding to mesothelin present 
on normal mesothelial cells lining the peritoneal cavity. The biochemical basis of this 
interaction between mesothelin and CA-125 was further characterized by Gubbels and 
colleagues [76]. Using the MUC16 expressing ovarian cancer cell line OVCAR-3, they 
showed that it binds mesothelin while OVCAR-3 derived sublines that do not express 
MUC16 do not bind mesothelin. They also showed that mesothelin has a very strong 
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affinity for MUC 16 with an apparent Kd of approximately 5 nM and that mesothelin 
interacts with both soluble and cell surface associated forms of native MUC16. Taking 
together these studies provide evidence that mesothelin and MUC16 binding may be 
important in the peritoneal spread of ovarian cancer. Inhibiting MUC16 binding to 
mesothelin could therefore be a potentially useful strategy to treat ovarian cancer. 
Mesothelin regulation by Wnt-1 and Wnt-5a 
The Wnt ligands are secreted glycoproteins that play an important role in intracellular 
signalling and regulate a variety of biological processes including cell growth, cell 
differentiation and apoptosis. A mis-regulation of Wnt signalling has been shown to 
lead to the development of several human cancers [77]. Using the mouse mammary 
epithelial cell line C57mg, Prieve and Moon showed that mesothelin was up-regulated 
by Wnt-1 both by the stable expression of Wnt-1 in C57mg cells and as well as by co-
culturing C57mg cells with Wnt-1 secreting cells [78].They also demonstrated that 
mesothelin expression was induced by Li+, an inhibitor of GSK-3b that mimics Wnt-1. 
In contrast to Wnt-1, Wnt-5a down-regulated mesothelin expression, perhaps through 
antagonism of endogenous Wnt/b-catenin signalling. These results suggest that 
mesothelin expression can be altered by Wnt proteins. Interestingly, mesothelin is 
highly expressed in mesothelioma, lung, ovarian, and pancreatic carcinomas, which 
have constitutive activation of Wnt signaling [62-79]. 
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Humoral anti-mesothelin immune response in cancer 
To determine whether a spontaneous humoral B cell response to mesothelin is present in 
patients with mesothelin expressing cancers Ho et al used a sensitive enzyme-linked 
immunosorbent assay (ELISA) to detect mesothelin-specific IgG antibodies in serum of 
patients with advanced mesothelioma and ovarian cancer [80]. Elevated levels of 
mesothelin-specific antibodies were detected in the sera of 27 of 69 (39%) patients with 
mesothelioma and 10 of 24 (42%) patients with epithelial ovarian cancer when 
compared with a normal control population. Mesothelin specific antibodies were present 
at a higher frequency in patients whose tumors had strong mesothelin expression by 
immunohistochemistry. These results suggest that the immunogenicity of mesothelin is 
associated with its high expression on the tumor cells and serologic recognition of 
mesothelin is cancer related. The presence of a mesothelin specific B-cell response in a 
significant proportion of patients with mesothelin expressing tumors supports ongoing 
efforts to use mesothelin as a therapeutic cancer vaccine. 
Prognostic significance of mesothelin expression in ovarian cancer  
The significance of tumor mesothelin expression with clinical outcome in ovarian 
cancer was studied by Yen and colleagues [81]. In this study, tumor mesothelin 
expression by immunohistochemistry was correlated with clinical outcome in 198 
patients with ovarian serous carcinoma. Mesothelin immunoreactivity was present in 
55% of serous carcinomas with similar expression in both high grade and low grade 
tumors. The results of this study showed that in patients with high-grade advanced-stage 
ovarian cancer treated with optimal debulking surgery and chemotherapy, diffuse tumor 
mesothelin immunostaining correlated significantly with prolonged survival. 
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Mesothelin expression did not correlate significantly with patient age, tumor site, tumor 
grade, in vitro drug resistance and tumor cell differentiation. The authors speculate that 
a humoral or T cell immune response to mesothelin-expressing ovarian carcinoma cells 
could result in reduction of tumor load leading to the prolonged patient overall survival. 
However, the prognostic significance of mesothelin expression in ovarian cancer and 
other mesothelin expressing tumours needs to be validated in large prospective studies. 
MESOTHELIN TARGETED THERAPIES  
The limited expression of mesothelin on normal human tissues and high expression in 
several human cancers makes mesothelin an attractive candidate for cancer therapy. 
These therapies include agents that target cell surface mesothelin or elicit an immune 
response against mesothelin. Agents that are in the clinic or about to enter clinical trials 
include CAT-5001, MORAb-009 and CRS-207. 
SS1P (CAT-5001) 
SS1P is a recombinant immunotoxin consisting of an antimesothelin Fv linked to a 
truncated Pseudomonas exotoxin that mediates cell killing [82-83].  After binding to 
mesothelin, the immunotoxin is internalized via clathrin coated pits, undergoes 
processing in the endocytic compartment and the immunotoxin fragment containing the 
ADP-ribosylation domain is transported to the endoplasmic reticulum and then 
translocated to the cytosol where it inhibits elongation factor- 2 leading to inhibition of 
protein synthesis and ultimately cell death [84]. Pre-clinical studies have shown that 
SS1P is cytotoxic to cell lines expressing mesothelin and causes complete regression of 
mesothelin expressing tumor xenografts in nude mice [63]. In addition SS1P is 
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cytotoxic to tumor cells obtained directly from human patients. Tumor cells obtained 
from patients with ovarian cancer undergoing surgery were grown in three dimensional 
organotypic cultures and treated with SS1P [85]. After treatment the organotypic gels 
were formalin fixed and evaluated for light microscopic examination and apoptosis. 
SS1P caused a dose dependent increase in tumor cell death and apoptosis. Similarly 
tumor cells established from ascites of patients with peritoneal mesothelioma are very 
sensitive to SS1P with an IC50 of 0.08–3.9 ng/ml [86]. These studies show that 
mesothelin is highly expressed on tumor cells obtained directly from patients with 
mesothelioma and are very sensitive to treatment with SS1P. Recent studies have 
looked at the anti-tumor activity of SS1P in combination with radiation therapy or 
chemotherapy. Athymic nude mice bearing A431/K5 mesothelin expressing tumors 
were treated with radiation alone, SS1P alone or the two agents in combination [87]. 
The results of this study showed that mice treated with low-dose radiation and SS1P or 
high-dose radiation and SS1P had a statistically significant prolongation in time to 
tumour doubling or tripling compared with control, SS1P or radiation alone treated 
mice. Two Phase I studies of SS1P have just been completed. These studies which were 
designed to test the safety, maximum tolerated dose (MTD) and pharmacokinetics of 
SS1P used two different strategies for SS1P administration. In one study SS1P was 
administered as an intravenous bolus infusion over 30 min (SS1P bolus infusion study) 
while as in the other study SS1P was given as a continuous i.v. infusion over 10 days 
(SS1P continuous infusion study). Since SS1P given as a bolus infusion has a prolonged 
half life and can be given at much higher dose and several patients showed anti-tumor 
response, this is the schedule that is being pursued for its further clinical development. 
Based on pre-clinical studies in animal models that show marked synergy when SS1P is 
Introduction – Mesothelin Targeted Cancer Immunotherapy 
45 
 
combined with chemotherapy, clinical trials of SS1P in combination with chemotherapy 
are about to start for the treatment of mesothelin expressing malignancies. 
MORAb-009 
MORAb-009 is a high-affinity chimeric (mouse/human) monoclonal IgG1/k with high 
affinity and specificity for mesothelin. The heavy and light chain variable regions of 
mouse antimesothelin scFv (obtained by panning on mesothelin-positive cells a phage 
display library made from splenic mRNA of a mouse immunized with mesothelin 
cDNA) were grafted in frame with human IgG1 and k constant regions. Since MORAb- 
009 is a chimeric antibody containing only the mouse sequences that recognize human 
mesothelin, it should be less immunogenic and allow repeated administration to 
patients. Laboratory studies show that MORAb-009 kills mesothelin expressing cell 
lines via antibody dependent cellular cytoxicity (ADCC) and in addition it inhibits the 
binding of mesothelin to CA-125. 
Based on these preclinical studies a Phase I clinical trial of MORAb-009 has been 
initiated (www.clinicaltrials.gov/ct/show/NCT00325494). 
CRS-207 
The rationale for mesothelin as a tumor vaccine is based on studies showing that 
mesothelin can elicit a strong CD8+ T cell response in patients [88]. One of the 
mesothelin cancer vaccines in advanced stages of clinical development is CRS-207 
(LmDactA/DinlB/hMeso). This vaccine utilises a live attenuated strain of the bacterium 
Listeria monocytogenes (Lm), a facultative intracellular bacterium, as the vector [89]. 
The engineered vector CRS-100, has deletions of the two genes that encode the 
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virulence determinants actA and internalin B (inlB), which results in a greater than 
1000-fold decrease in virulence compared to the wild type Lm. CRS-100 is currently 
undergoing Phase 1 testing in patients with carcinoma and liver metastasis [90]. CRS-
207 is a live-attenuated Lm vaccine strain based on CRS-100 that encodes human 
mesothelin. Preclinical studies show that CRS-207 elicits human mesothelin-specific 
CD4+/CD8+ immunity in mice and in cynomolgus monkeys and exhibits therapeutic 
efficacy in tumor bearing mice [91]. A Phase I clinical trial of CRS-207 for the 
treatment of patients with mesothelin expressing cancers is about to commence. 
Mesothelin cancer vaccines 
The utility of mesothelin as a tumor vaccine came from a clinical trial conducted by 
Jaffe and colleagues that involved vaccination of pancreatic cancer patients with GM-
CSF transduced pancreatic cancer cell lines [92]. Out of the 14 patients treated on this 
study 3 developed a post vaccination delayed-type hypersensitivity (DTH) response to 
the autologous tumor, that was associated with prolonged survival [92]. Subsequent 
immunologic studies showed that a strong and consistent induction of CD8+ T cell 
response to multiple HLA-A2, -A3, and -A24-restricted mesothelin epitopes occurred 
exclusively in the three patients who had developed a vaccine induced DTH response 
[88]. In another vaccine study, T-cell lines derived from the native or the agonist 
mesothelin epitope were shown to lyse mesothelin expressing and HLA-2 positive 
pancreatic cancer, ovarian cancer and mesothelioma cell lines [93]. These studies 
support the potential utility of mesothelin in peptide and/or vector-mediated 
immunotherapy protocols for the treatment of cancers that highly express mesothelin. 
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Mesothelin targeted ovarian cancer gene therapy 
Pre-clinical studies have evaluated mesothelin as a target for adenoviral-mediated gene 
therapy. Adenoviruses containing the mesothelin promoter driving reporter gene 
expression were evaluated using established ovarian cancer cell lines and purified tumor 
cells obtained from patients [94]. These studies showed that the mesothelin promoter is 
transcriptionally active in ovarian cancer cells but has significantly reduced activity in 
normal control cells. Also in the liver, which does not express mesothelin, mesothelin 
promoter activity was low making it a useful promoter for gene therapy. The utility of 
mesothelin for transductional gene therapy, i.e. to direct gene therapy agents to targets 
highly expressed in specific tumors was also evaluated in this study. An adenovirus 
vector containing Fc-binding domain was conjugated to the mouse anti-human 
mesothelin mAb. This transductional targeting to mesothelin led to increased 
transduction rates in ovarian cancer cell lines as well as tumor cells obtained from 
patients. In contrast there was no increase in gene transfer rate using this construct in 
mesothelin negative human fibroblast cells or the teratocarcinoma cell line PA-1. These 
results show that mesothelin could be a potentially useful candidate for combined 
transductional and transcriptional adenovirus-based gene therapy. 
Mesothelin as a target for radioimmunotherapy 
Mesothelin as target for radio-immunotherapy was evaluated in vivo using nude mice 
bearing mesothelin expressing A431/K5 xenografts [95]. This study used a pre-targeting 
strategy that involves the administration of streptavidin (SA)-conjugated antibody to 
target the tumor, administration of a clearing agent to remove any circulating antibody-
SA conjugate from the blood and then the injection of radiolabelled biotin that localizes 
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to tumor tissue bearing SA-conjugated antibody. Mice bearing A431/K5 tumors were 
first injected with the anti-mesothelin tetravalent single-chain Fv-streptavidin fusion 
protein (SS1scFvSA) followed 20 h later by a synthetic clearing agent to remove any 
unbound SS1scFvSA. This was followed 4 h later by the administration of radiolabelled 
90Y-1,4,7,10-tetraazacyclododecane- N,N‘,N‘‘,N‘‘‘-tetraacetic acid (DOTA)-biotin. 
Pretargeted therapy of A431/K5 tumor with 90Y doses of 11.2–32.4 MBq resulted in a 
dose-dependent tumor response. In mice that were treated with 32.4 MBq of 90Y, 86% 
survived tumor free for 110 days compared to a median survival of only 16 days in the 
untreated mice.Such a pre-targeted approach could potentially be useful in the clinic and 
reduce non-specific bone marrow toxicity. 
However, the high immunogenicity of SA, could limit repeated administration of this 
agent.
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The generation of an immunotoxin involves the chemical coupling or genetic fusion of a 
cell-selective ligand with a complete toxin or a modified form of the toxin. The ligand 
provides the cell binding and internalizing property, whereas the toxin inhibits crucial 
cell function and causes cell death upon translocation to the cytosol. The ligand can be a 
recombinant antibody or an antibody fragment, growth factor, carbohydrate antigen or 
tumor-associated antigen. Bacterial toxins, such as Pseudomonas exotoxin (PE) and 
diphtheria toxin (DT), and plant toxins, such as ricin, saporin, gelonin and poke weed 
antiviral protein, are used in immunotoxin constructs [96]. The advantages of this 
approach over chemotherapy are the selective delivery of drugs to tumors, thereby 
reducing systemic toxicity and increasing potency. 
The first generation of immunotoxins, developed 35 years ago, employed chemical 
conjugates of antibodies with intact toxins, or toxins with attenuated cell-binding 
properties. Although they showed tumor regression in some lymphoma patients, they 
were typically ineffective because the constructs were heterogeneous, nonspecific and 
were too large to infiltrate solid tumors [97]. The next generation also employed 
chemical conjugation with deletions in native cell-binding domains, generating many 
more target-specific immunotoxins. Recombinant DNA techniques were applied in the 
production of third-generation immunotoxins to promote tumor specificity and 
penetration, and to reduce the cost and complexity of production. The cell-binding 
domain of the toxin is genetically removed and the modified toxin fused with a ligand 
or with DNA elements encoding the Fv portion of an antibody in these constructs. The 
light- and heavy-chain variable fragments are either genetically linked (scFv) [98-99] or 
held together by a disulfide bond (dsFv) [100]. Compared with the single-chain toxins 
(scFv), disulfide-stabilized Fv (dsFv) molecules did not aggregate, were stable and also 
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overcame the major obstacle of poor penetration into bulky tumor masses. These 
targeted toxins posed problems such as immunogenicity, nonspecific toxicity and 
instability [100]. The identification and mutation of B-cell epitopes in PE and their 
incorporation into immunotoxins reduced the immunogenicity of the toxin [101]. A new 
field of immunotoxins called bispecific immunotoxins (DT2219ARL) has also emerged 
recently – involving the simultaneous specific targeting of two targets on cancers for 
increased efficacy and reduced nonspecific toxicity [102]. Recent endeavors involve a 
new generation of immunotoxins in which the cytotoxic moiety is an endogenous 
protein of human origin, for example proapoptotic protein or RNase [103]. At present, 
only one agent, denileukin diftitox, which is a fusion protein of truncated DT and 
interleukin 2 (IL2), has been approved by the FDA [104]. Several similar fusion 
proteins are currently in clinical trials.  
IMMUNOTOXIN DEVELOPMENT 
A variety of toxins, mainly from plants, fungi or bacteria, have been characterized, 
structurally optimized for in vitro stability, activity and safety, and evaluated in vivo in 
animal studies and clinical trials. Among them, ricin, PE and DT are the most frequently 
used.  
Immunotoxins with RNases as the cytotoxic moiety are recent examples aimed at 
reducing the immunogenicity. These toxins generally consist of several domains – the 
cell-binding or cell-recognition domain, the translocation domain, which enables release 
of the toxin into the cytosol, and the activity domain responsible for cytotoxicity.  
In immunotoxin development the binding domain of these toxins is replaced by the 
cancer-cell-specific ligands.  
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The cancer-cell-specific ligands direct the internalization of the toxins via receptor-
mediated endocytosis.  
Upon internalization the catalytic domain of the toxin is cleaved in the late endosome 
and translocates to the cytosol leading to cell death by various mechanisms (Figure 8).
 
Fig. 8 Mechanism of action of immunotoxins. Immunotoxins enter the cell via receptor-mediated 
endocytosis. Upon binding to a cell-specific receptor, the toxin receptor complex is internalized through 
clathrin-coated pits into an endosome. For PE and DT, low pH induces unfolding of the protein, 
proteolytic cleavage and the release of the activity domain in the cytosol, where it inhibits protein 
synthesis by ADP ribosylation of the diphthamide residue of elongation factor 2 (EF2). 
Release of ricin in the cytosol leads to N-glycosylation of residues in 28S rRNA and prevents association 
of EF1 and EF2 with 60S ribosome, while restrictocin cleaves the 28S rRNA and leads to protein 
synthesis inhibition. Cholera toxin acts by ADP ribosylation of the Gs-a subunit of G proteins leading to 
an increased cAMP level and pore formation in the membrane resulting in cell death. 
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Table 3 represents the classification of clinically used toxins based on their mechanism 
of action. Many modifications in the toxin fragments have enabled improvements in 
cytotoxic activity and reduced immunogenicity over the years. The modified form of the 
toxins has also been identified in Table 3. 
 
Abbreviations: DT: diphtheria toxin; DT388 or DT389: truncated forms of DT that lack receptor-binding 
activity: CRM107 or cross-reacting material – mutant of DT lacking receptor binding; PE: Pseudomonas 
exotoxin A; PE40 and PE38: truncated forms of PE that lack receptor-binding domain Ia; CET40: cholera 
exotoxin A; RTA: ricin toxin A; HPR: human pancreatic ribonuclease A; ECP: eosinophilic cationic 
protein; EDN: eosinophil-derived neurotoxin (Drug Discovery Today – Volume 16, Issues 11-12 – April 
2011). 
 
In this work of thesis our group decided to synthesize a chemical linked immunotoxin 
(IT) by use Ricin Toxin A (RTA). RTA belongs to Ribosome Inactivating Proteins 
(RIPs); the advantage of using RIPs is that rigorous purification to eliminate the B-chain 
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is not necessary. Moreover, no authors described an anti mesothelin antibody chemical 
linked to RTA to target such cancers. 
RIBOSOME INACTIVATING PROTEINS BASED IMMUNOTOXINS  
RIPs are a group of proteins that share the property of damaging ribosomes in a 
reversible manner, acting catalytically, i.e enzimatically. RIPs have been used to 
prepare immunotoxins or other conjugates, either by chemical linkage or as 
recombinant fusion proteins mostly with monoclonal antibodies but also with other 
suitable carriers, e.g. hormones (hormonotoxins), cytokines, neuropeptides. Currently, 
RIPs are divided into two groups, type 1 RIPs, consisting of a single peptidic chain of 
30 kDa, approximately, and type 2 RIPs which, as found by Olsnes and Pihl (1973), 
consists of an enzimatically active A chain similar to type 1 RIPs, linked to a slightly 
larger (35 kDa, approx.) B chain, which has the properties of a lectin with specificity for 
sugars with the galactose structure [105]. It was proposed to include in a type 3 group 
two other proteins. One is a maize b-32 RIP, which is synthesized as a proenzyme, 
activated after the removal of a short internal peptide segment leaving two segments of 
16.5 and 8.5 kDa [106]. The other one is JIP60, a RIP from barley in which a segment 
similar to type 1 RIPs continues with another segment of similar size without a known 
function [107]. More recently, it was suggested to include only the latter into this group 
[108]. A schematic representation of RIPs structure is in Figure 9. 
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Fig. 9. Schematic representation of the structure of ribosome-inactivating proteins (Stirpe F., et al., 2004). 
Distribution in nature and mechanism of action 
RIPs were initially detected in plants, mostly in Angiopermae, both mono- and 
dicotyledons, and also in mushrooms [109-110], and in an alga, Laminaria japonica 
[111]. The level of RIPs in plant tissues is highly variable, ranging from traces to 
hundreds of milligrams per 100 g. In some plants, RIPs are present in many or even in 
all tissues examined (roots, leaves, stems, bark, flowers, fruits, seeds, latex, cultured 
cells), whilst in other plants they are confined to a single tissue. RIPs are not limited to 
plants and an enzymatic activity similar to that of RIPs was detected in animal cells and 
tissues which, like in plants [112], was higher in virally-infected and stressed cells 
[113]. 
The mechanism of the ribosomal damage was discovered by Endo et al. (1987), who 
found that ricin cleaved the glycosidic bond of a single adenine residue (A4324 in rat 
liver rRNA). This residue is adjacent to the site of cleavage of rRNA by α-sarcin, in a 
Chapter III (Ribosome inactivating protein) 
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tetranucleotide GA4324GA in a highly conserved loop at the top of a stem, for this called 
α-sarcin/ricin loop (Figure 10). This observation was extended to other RIPs [114], 
which were officially classified as rRNA N-glycosidases (rRNA N-glycohydrolases, EC 
3.2.2.22). 
 
Fig. 10 Schematic representation of the enzymatic action of ribosome-inactivating proteins on rRNA, 
RIPs cleave a single adenine base (A4324 in 28 S rat mRNA) at a site adjacent to the site of attack by α-
sarcin, which cleaves the phosphodiester bond between G4325 and A4326 in rat 28 S rRNA. 
 
Subsequently, it was found that (i) some RIPs remove more than one adenine residue 
per ribosome [115] and (ii) that RIPs remove adenine residues from DNA and other 
polynucleotides [116-117-118]. 
A summary of the properties of RIPs is given in Table 4 (Stirpe F., et al., 2004). 
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Toxicity 
Until recently it was assumed that all type 2 RIPs were potent toxins. The high toxicity 
was explained by the binding of the B chain to the surface of most cells. This occurs 
through binding of the lectin site to galactosyl-terminated residues on most cells. Once 
bound to cells, the B chain allows and facilitates the entry of the toxins in the cells, 
where the A chain can exert its enzymatic activity, damaging ribosomes and possibly 
other structures, with consequent cell damage and death. 
Type 1 RIPs, being devoid of a B chain, enter with difficulty into cells and consequently 
are much less toxic than type 2 RIPs, but become highly toxic if they are introduced into 
cells by linkage to an appropriate carrier capable of binding to cells. 
The cytotoxicity of RIPs is commonly attributed to the inhibition of protein synthesis 
consequent to ribosomal damage. However, this view was challenged when it was 
found that ricin induced the expression of Apo2.7 [119] and Bak [120], suggesting that 
de novo protein synthesis occurred in the apoptotic process triggered by the toxin. 
Furthermore, it was observed that ricin and Shiga toxin cause disruption of DNA in 
human endothelial (HUVEC) cells, in a manner that appeared before the activation of 
caspase 3 [121]. This alteration occurred simultaneously to protein synthesis inhibition 
in the case of ricin, and shortly afterwards in the case of Shiga toxin, and was not 
observed when a comparable inhibition of protein synthesis was induced with 
cycloheximide. Furthermore, saporin caused damage to genomic DNA [122], and it was 
concluded that both the rRNA glycosidase activity and the DNA internucleosomal 
fragmentation contributed to cell death. All this suggests that multiple effects of RIPs 
on nucleic acids may concur to the pathogenesis of cell damage. 
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Immunotoxins and other conjugates 
RIPs of both types have been used, although toxic type 2 RIPs as such are not suitable, 
because their B chains would bind unselectively to virtually any cell. This difficulty has 
been circumvented either by the use of isolated A chains, that of ricin being the most 
commonly employed, or, less frequently, with the use of ‗blocked ricin‘, in which 
galactose-binding sites are modified and rendered ineffective, or with the use of 
nontoxic type 2 RIPs, e.g. ebulin 1 [123]. Immunotoxins have been prepared also with 
type 1 RIPs, especially PAP, saporin and gelonin.  
Most immunotoxins have been prepared for the experimental therapy of malignancies, 
for immunosuppression and also for the therapy of viral diseases. For these purposes 
RIPs have been linked to antibodies against antigens expressed prevalently on cancer 
cells [124] or on endothelial cells of tumor vasculature [125-126], on immunocompetent 
cells [127] or on cells infected by viruses, especially by HIV [128-129]. Immunotoxins 
work very well in vitro, in that with them, at appropriate concentrations, it is possible to 
eliminate target cells without too much damage to other cells, and under this respect 
they seem to be most valuable tools to remove contaminating cells from cell cultures. 
In medicine, studies have been done to use immunotoxins in vitro to purge bone marrow 
suspensions from malignant or immunocompetent cells but, again, their use in therapy 
is not common. 
A number of experimental studies have been done with tumors transplanted in animals. 
Results have been very encouraging, especially when treatment was started soon after 
the inoculum of tumors [130], suggesting that immunotoxins are more efficient on small 
cell masses. Consistently, better results were obtained with haematological than with 
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solid tumors, suggesting that a first difficulty with immunotoxins in vivo is their arrival 
to, and entry into, tumor cells. 
Other applications were envisaged. Among these, immunotoxins were prepared with 
ricin [131] or saporin [132] and antibodies against the acetylcholine receptor.  
These immunotoxins selectively damage muscles and are proposed, as an alternative to 
botulinum toxin, for the therapy of spasm or of strabismus [133-134-132].  
A conjugate of saporin with substance P has been developed and proposed for the study 
and therapy of pain [135]. Clinical trials with immunotoxins were performed, most of 
them for treatment of cancer [136-124].  
The results were encouraging, but still some problems prevent the use of immunotoxins 
in human therapy. As a whole, the side effects they cause are not worse than those of 
many conventional chemotherapy treatments, and include fever, fatigue, myalgia, and 
capillary leak syndrome. Repeated administration of immunotoxins is prevented by the 
immune response they elicit in the recipient organism.  
Currently, this is a major obstacle to the therapeutic use of immunotoxins, which 
hopefully will be reduced, if not prevented, either by better immunosuppressive 
treatments, or by the use of humanized antibodies and possibly of recombinant human 
enzymes
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AIM OF THE THESIS 
Aim of this thesis was to develop new mAbs direct to the tumor associate antigen 
(TAA) mesothelin. Mesothelin is overexpressed in a variety of cancers including 
mesothelioma, ovarian cancer and pancreatic cancer. In addition, mesothelin is 
expressed on the surface of many lung adenocarcinomas and other types of lung cancer.  
The generation of new mAbs mesothelin targeting can be a promising approach for 
therapeutic anti cancer applications (based on immunoconjugates spread toxin or 
chemotherapeutic agents) and diagnostic for imaging applications (by means of 
radioactive or fluorescence trackers). 
Presently, drugs that are in the clinic or about to enter clinical trials for treatment of 
mesothelin overexpressing tumors include SSP1 (CAT-5001), that is a recombinant 
immunotoxin consisting of an antimesothelin murin scFv linked to a truncated 
Pseudomonas exotoxin A of Pseudomonas Aeruginosa and MORAb-009 that is a 
chimeric (mouse/human) mAb containing the same murin scFv of SSP1.  
Our group decided to produce new mAbs recognizing mesothelin for these reasons:  
- mAb to mesothelin is not already available, due to patent restrictions; 
- potential availability of almost infinite quantities of a specific monoclonal 
antibody directed toward a single epitope; 
- mAb cDNA can be used  to engineer the protein to create single chain-variable 
fragments (scFvs), multivalent scFvs (diabodies, tribodies), minibodies (scFv-
CH3 dimers), bispecific antibodies;  
- mAb could be used for emerging nanoparticle technologies; 
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- production of chimeric and humanized mAbs to reduce the immunogenicity and 
to increase the immune system activation (ADCC antibody-dependent cell 
cytotoxicity and CDC complement-dependent cytotoxicity). 
My work describes the development of a new anti-mesothelin mAb and the following 
functional characterization. The mAb that I have produced was obtained by hybridoma 
technologies. This antibody was tested by flow cytometry to evaluate the specificity and 
affinity for the antigen mesothelin. Subsequent goal of this project was to synthesize a 
chemical linked IMMUNOTOXIN (IT) conjugating the mAb anti mesothelin with the 
powerful plant toxin Ricin A (RTA) and to study the effects of this IT on mesothelin 
positive and negative cell lines by XTT assay.  
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MATERIAL AND METHODS 
PLASMID pcDNA3.1 STRUCTURE 
The pcDNA3.1(+) (Invitrogen) is a vector of about 5400 bp (Figure 11) for constitutive, 
high level expression of recombinant protein in mammalian cells. This plasmid contains 
a promoter sequence deriving from Cytomegalovirus (CMV) for a useful transcription 
of the cloned gene, and a bovine growth hormone (BGH) polyadenylation signal for the 
efficient transcription termination and polyadenylation of mRNA. It contains T7 
promoter/priming site that allows in vitro transcription in the sense orientation and 
sequencing through the insert multiple cloning site in forward or reverse orientation that 
makes insertion of your gene possible and facilitates cloning. It presents pUC origin for 
high-copy number replication and growth in E. coli. The vector is composed also by the 
f1 (phago filamentous) origin that consents rescue of single-stranded DNA. Moreover, it 
is made up by SV40 early promoter and origin which allow efficient high-level 
expression of the neomycin resistance gene and episomal replication in cells expressing 
SV40 large T antigen. It presents also SV40 early polyadenylation signal for a useful 
transcription termination and polyadenylation of mRNA. Finally, pcDNA3.1 is made of 
Ampicillin resistance gene (β-lactamase) for selection of vector in E. coli and neomycin 
resistance gene for the choice of stable transfectants in mammalian cells. 
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Fig. 11 The figure summarizes the features of the pcDNA3.1(+) vector (www.invitrogen.com).  
CELL LINES 
The cell lines were purchased from ATCC (American Type Colture Collection, 
Rockville, MD,USA). These cell lines included: 
- Human embryonic kidney cell-line (HEK293); 
- Human ovarian  carcinoma cell line (OVCAR-3); 
- Rat glial tumor cell line (C6); 
- Human leukemic monocyte lymphoma cell line (U937); 
- Human T cell lymphoblast-like (lymphoma) cell line (Jurkat); 
- Human prostate cancer cell line (PC3); 
- Human epithelial carcinoma cell line (A431); 
- Human acute lymphoblastic T cell leukemia (CEM); 
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HEK293 cell line transfected with mesothelin (HEK293-mesothelin) was produced in 
our laboratory by the transfection into HEK293 of pcDNA3.1-mesothelin. The cells 
were cultured in D-MEM (Dulbecco‘s Modified Eagle Medium, Biochrom AG, Berlin, 
Germany) or in RPMI-1640 supplemented with 10% FBS (Fetal Bovin Serum), L-
Glutammine 2mM, penicillin–streptomycin 100 U/ml, HEPES 10 mM. The medium of 
the HEK293 was added with 500 μg/ml of G418 (Geneticin® reagent is an 
aminoglycoside related to Gentamicin and it is commonly used as a selective agent for 
eukaryotic cells, Gibco). Cells were then incubated at 37 °C with 5% CO2 in a 
humidified atmosphere. 
PRODUCTION OF RECOMBINANT MESOTHELIN 
pET30a - mesothelin vector was transfected into the host strain, E. Coli BL21 DE3. The 
bacteria were triggered overnight in 100 ml of Lysogeny broth (LB) - plus kanamycin 
(1:1000), a nutritionally rich medium. 20 ml of this pre-culture were grown at 37°C in 1 
liter of medium (in a stirrer) and they were induced in the logarithmic phase at OD600nm 
value = 0,7 – 0,8 with 1 mM isopropyl β-D-thiogalactoside (IPTG) and cultured at 37°C 
for 3 h. The recombinant protein was obtained as cytoplasmic inclusion bodies. At this 
stage, the bacteria were centrifuged, and the pellet was lysated by sonication in 
inclusion bodies (IB) buffer (Tris 20 mM pH 7.5, EDTA 10 mM and Triton X-100 1%, 
lysozime, Dnasi I, PMSF and complete protease inhibitors). Cytoplasmic inclusion 
bodies‘ pellet was washed twice with IB buffer and then solubilized at 20 mg/ml in a 
solubilization buffer (CAPS 10X, DTT 1mM, N-lauroylsarcosina 1,2%). 
Protein refolding method was obtained by sequential dialysis steps at 4°C: 
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- 1st and 2nd steps dialysis (Volume = 50X) Tris HCl 1 M pH 8.5 + DTT 0.1 mM + 
PMSF 0.1 mM; 
- 3rd and 4th steps dialysis (Volume = 50X) Tris HCl 1 M pH 8.5 + PMSF 0.1 mM; 
- 5th step dialysis (Volume = 25X) Tris HCl 1 M pH 8.5 + PMSF 0.1 mM + L-
Arginine 0.4 M + GSSG 0.5 mM + GSSH 5 mM; 
- 6th dialysis (V = 100X) TP 5mM PH 8.0. 
The purification was achieved by affinity chromatography taking advantage from 
the affinity of the imidazole rings of poly – histidine tails of His-tagged recombinant 
mesothelin for the resin Ni-NTA His Bind Resin (Novagen). The protocol was used 
as follows: 
- Ni-NTA resin (column) was equilibrated with binding buffer (TP 5 mM pH 8.0); 
- After centrifugation, the sample was incubated overnight with the resin and then 
filtrated twice through the column; 
- Three washes were performed with wash buffer (TP 5 mM pH 8.0 imidazole 10 
mM) to eliminate possible bacteria proteins (these proteins bind the resin in a 
not specific way); 
- Finally, recombinant protein was eluted repeatedly with eluition buffer (TP 
5mM pH 8.0 imidazole 250 mM). The eluitions were analyzed by 
spectrophotometer reading and polyacrylamide gel electrophoresis to establish 
the proteic content. 
The validation of the production of a protein dimensionally corresponding to the 
mesothelin was obtained by polyacrylamide gel electrophoresis, whereas the definitive 
confirmation of the proteic identity was achieved through western blot (WB). 
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TRANSFECTION 
The transfection was performed with LIPOFECTAMINE 2000 (Invitrogen), that is a 
reagent of transfection containing cationic liposome. The HEK293 wt cells were 
transfected with pcDNA3.1 containing the gene that expresses the mesothelin. 
The cells were seeded in a 24-wells plate and the transfection was performed as follows 
(manufacturer protocol): 
- the day before transfection 1.5x105 cells/well in 0.5 ml of complete growth 
medium were seeded and they were placed in incubator overnight (cell density 
should be 50-80% confluent on the day of transfection); 
- the day of transfection, the DNA of interest (0.3 μg) was diluted in 250 μl of 
Opti-MEM medium (Invitrogen) for each well of cells to be transfected, as well 
as 1 μl of Lipofectamine was added into the above diluted Opti-MEM-DNA 
solution, mixed gently and incubated for 30 minutes at room temperature to 
form DNA/Lipofectamine complexes; 
- subsequently, the medium of growth was removed from the wells and the 
complexes DNA/Lipofectamine was adjoined directly to each well containing 
cells. Opti-MEM medium was added to each well until the total volume was of 
500 μl/well. The cells were incubated at 37°C in a CO2 incubator for about 6 
hours and then 2 ml/well of complete D-MEM were adjoined. The reaction 
lasted overnight. 
- next morning, for each well of cells G418 antibiotic (500 μg/ml) was added for 
the selection of cells steadily transfected; 
After 48 hours from the transfection, FACS analysis was performed to evaluate the cells 
expressing the construct of interest.  
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BALB/c MICE IMMUNIZATION FOR ANTI-MESOTHELIN ANTIBODY 
PRODUCTION 
Immunization protocol involves the preparation of antigens samples and their safe 
injection into laboratory or farm animals so as to evoke high-expression levels of 
antigen-specific antibodies in the serum. BALB/c immunization was performed by 
injection of cells membranes that overexpress the antigen mesothelin. The first 
immunization (day 0) was done with HEK293-mesothelin cells membranes by an intra-
peritoneal (i.p) injection with about 500 μg of total membrane proteins suspended again 
in 400 μl of physiologic solution (NaCl 0.9%) emulsified in complete Freund‘s adjuvant 
(Sigma Aldrich). After 7 days (day 7), a booster was performed with OVCAR-3 cells 
membranes (i.p injection) emulsified in Freund‘s incomplete adjuvant. After 10 days 
(day 10), the serum was recovered from the animal to evaluate the presence of anti-
mesothelin antibodies. It is important to remind ourselves here that antisera generated in 
this way also contained considerable amounts of other antibodies directed against a 
variety of membrane antigenic determinants (these antisera were said to be polyclonal). 
The presence of anti-mesothelin antibodies was confirmed by FACS analysis on 
mesothelin positive cells and mesothelin negative cells. Subsequently, the final boost 
was performed by a combination of two immunizations at the same time: an intra-
venous (i.v) injection of 10 μg of recombinant mesothelin and an i.p injection with cells 
membranes of HEK293-mesothelin at -3, -2, -1 days from the splenectomy. The final 
boost was used for two purposes: to induce a good strong response and to synchronize 
the maturation of the response. This boost was done at least 3 weeks after the previous 
injection. This interval allowed most of the circulating antibodies to be cleared from the 
blood stream by the mouse. 
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ADJUVANTS 
To enhance the immune response to an immunogen, various additives called adjuvants 
can be used. When mixed and injected with an immunogen, an adjuvant will enhance 
the immune response. This is not a substitute for a carrier protein, because it enhances 
the immune response to immunogens but cannot itself make haptens immunogenic. 
Adjuvants are nonspecific stimulators of the immune response, helping to deposit or 
isolate the injected material and causing a dramatic increase in the antibody response. 
There are many popular adjuvants, including Freund‘s complete adjuvant (FCA). This 
reagent consists of a water-in-oil emulsion and killed Mycobacterium. The oil-and-
water emulsion localizes the antigen for an extended period of time, and the 
Mycobacterium attracts macrophages and other appropriate cells to the injection site. 
Inject Freund‘s Complete Adjuvant is used for the initial injections. Subsequent boosts 
use immunogen in an emulsion with inject Freund‘s Incomplete Adjuvant, which lacks 
the Mycobacterial component. Freund‘s adjuvants are very effective, but they do pose 
risks to both animal and researcher because of the toxic Mycobacterial components. 
PREPARING MACROPHAGE FEEDER CELL CULTURES 
The macrophages were isolated from the peritoneal cavity of a mouse washing the 
cavity with RPMI-1640 medium cold (to promote macrophage detachment). The 
macrophages diluted in RPMI-1640 were seeded in a 24-wells plate and incubated at 
37°C in a 5% CO2 incubator. 
After 12 hours, each well was washed with RPMI-1640 and the medium of incubation 
was substituted with fresh complete RPMI-1640 medium. The macrophages were 
irradiated with a Cs source irradiator at 6000 rad. In this way, the macrophages lose the 
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ability to proliferate even if they are able to secrete cytokines that stimulate the growth 
of the hybridomas.  
PREPARING SPLENOCYTES FOR FUSION 
The mouse was sacrificed. The spleen was removed aseptically from an immunized 
animal and placed in a 100-mm tissue culture dish containing 10 ml of medium without 
serum (RPMI-1640). Contamination tissue was trimmed off and discarded from the 
spleen. 
The spleen was teased apart using 19-gouge needles on 1.0-ml syringes (continue to 
tease until most cells have been released and the spleen has been torn into very thin 
parts). Cell clumps were disrupted by pipetting. The cells and medium were moved into 
a sterile centrifuge tube (on ice). In this way the cells were transferred leaving behind 
larger pieces of tissue. The tissue culture plate and tissue clumps were washed with 10-
ml of medium without serum (RPMI-1640) and combined with the first 10 ml in the 
tube. 
The cell suspension was allowed to sit for approximately 2 min. This permitted larger 
cell clumps to settle to the bottom of the tube. The supernatant was carefully removed 
from the sediment and transferred to a fresh centrifuge tube. 
A spleen from an immunized mouse contains approximately 5x10
7 
to 2x10
8 
lymphocytes. 
PREPARING MYELOMA CELLS FOR FUSION 
Myeloma cells were thawed from liquid nitrogen stocks at least 6 days prior to the 
fusion. The myeloma cells were grown rapidly and healthy before the fusion in 
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complete RPMI-1640 20% FCS (fetal calf serum). A day before, the cells were splitted 
into fresh medium at a final concentration of 5x10
5 
cells/ml. In this way, the morning of 
the fusion myeloma cells were at least 2x10
7
. 
FUSION PROTOCOL 
The technique of hybridization of an immortal myeloma cell line with an antibody-
producing B cell, as developed by Kohler and Milstein in the late 1970s, provided a 
technique by which monoclonal antibodies could be produced in virtually unlimited 
quantities. Since the technique involved the selection of single cells and the clonal 
expansion of a single hybrid between the antibody-forming cell and the myeloma cell, it 
made available, for the first time, monoclonal antibodies for usage in cancer biology 
(Figure 12). 
 
Fig. 12 Production of mAb: use of hybridoma technology. 
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Cell fusion induced by polyethylene glycol (PEG) has become a standard method in 
somatic cell genetics. PEG promoting cell fusion is also the standard procedure for the 
production of hybridoma cells.  
Myeloma cells and splenocytes were mixed in a ratio 1:7, respectively. The cellular 
suspension was centrifuged at 250 x g for 10 minutes at 20°C. 
After the centrifuge, the supernatant (medium) was carefully removed as completely as 
possible with a Pasteur pipette. A complete removal of the supernatant is essential to 
avoid dilution of PEG. The pellet was broken by gently tapping the bottom of the tube. 
The tube was placed in a 37°C water bath and kept there during the fusion. 
1 ml of 50% PEG 1500 pre-warmed was added to the pellet using 1 ml pipette, over a 
period of 1 minute, constantly stirring the cells with the pipette tip. 
Stirring the cells in 50% PEG 1500 was carried on for a further1-2 minutes. 
1 ml of medium without serum (RPMI-1640) pre-warmed at 37°C was adjoined to the 
fusion mixture, continuously stirring as before, over a period of 1 minute. 
3 ml of medium without serum (RPMI-1640) pre-warmed at 37°C was added over a 
period of 3 minutes, continuously stirring the cells. 
10 ml of medium without serum (RPMI-1640) pre-warmed at 37°C was adjoined slowly 
and the pellet was incubated for 5 minutes at 37°C. 
The cells were centrifuged and the supernatant was discarded. The pellet was suspended 
again in complete RPMI-1640 20% FCS.  
The cellular suspension was seeded in the 24-wells plate previously treated with 
macrophage irradiated (see p. 53 ―preparing macrophage feeder cell cultures‖) and 
incubated at 37°C in a 5% CO2 incubator. 
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After 24 hours, the medium of incubation was added with hypoxanthine-aminopterin-
thymidine (HAT - Sigma) supplemented medium. Aminopterin blocks the synthesis of 
DNA by inhibiting dihydrofolate reductase. Cells that lack the ability to use the rescue 
pathway for nucleotide synthesis are eliminated. Cells that possess hypoxanthine – 
guanine phosphoribosyl transferase (HPRTase) and thymidine kinase (TK) enzymes can 
exploit the salvage pathway if supplied with hypoxanthine and thymidine. The purpose 
of the medium was: (1) selectively kill unfused myeloma cells that are well adapted to 
the tissue culture and that would otherwise outgrow any hybridomas produced and (2) 
eliminate any myeloma-myeloma hybridomas that lack HPRTase. HPRTase positive 
spleen-spleen hybridomas, although not sensitive to aminopterin, are normally short-
lived in culture. In this way, only the B cell-myeloma hybrids survive. These cells 
produce antibodies (a property of B cells) and are immortal (a property of myeloma 
cells). Wells containing hybridomas were ready to start screening 14 days after the 
fusion. The first step was to collect the supernatant from the wells having hybridomas 
density 80-100% confluent and to test this supernatant by FACS analysis on mesothelin 
positive cells and mesothelin negative cells, to evaluate the presence of anti- mesothelin 
antibodies. Hybridomas positive to the screening (at this stage they were said to be 
polyclonal hybridomas) were cloned by limiting dilution in 96-wells plate. Because 
hybridoma cells have a very low plating efficiency, single cell cloning was done in the 
presence of macrophage feeder cells. After selection is complete (about 14 days), the 
supernatant of the hybridomas was tested by FACS analysis to verify the presence of 
hybridomas producing anti-mesothelin antibodies (at this stage they were said to be 
monoclonal hybridomas). Positive hybridomas were expanded and adapted to 
Hybridomed culture medium (Bichrom AG, Berlin, Germany). The medium was added 
Material and Methods 
72 
 
with penicillin/streptomycin 2 mM. The adaptation of the hybridomas was performed 
gradually to avoid the hybridomas‘ death. The aminopterin is diluted from the culture 
by several passages of the cells in hypoxanthine-thymidine (HT, Sigma Aldrich, S. 
Louise, USA) supplemented medium (approximately 2-3 weeks) before transferring 
into normal hybridoma growth medium. The passages were from 100% of HAT to 75%, 
50%, 25%, 0% of HAT and at the same time from 0% of HT to 25%, 50%, 75% and 
finally to 100% of HT. 
Subsequently, the hybridomas were adapted gradually at the RPMI-1640 20% FCS 
medium and then they were transferred in Hybridomed, that is a specific hybridoma 
growth medium. Each time the medium was changed, the hybridomas were analyzed by 
FACS to confirm the specificity of the same ones against the antigen mesothelin. 
FACS (Fluorescence Activated Cell Sorter) 
The expression of antibodies anti-Mesothelin was evaluated on different cell lines as 
follows: 
Cells from monolyer cultures were detached with Trypsin-EDTA 0.02%, neutralized 
with medium of culture and thus harvested. The cells were counted and 2.5x10
5
/3x10
5 
cells were placed in each tube. The cells were washed twice with physiologic solution 
(NaCl 0.9%) at 4°C and incubated with 100 µl of supernatant of the hybridomas for 1 
hour on ice. 
After 1 hour of incubation, cells were washed with physiologic solution (NaCl 0.9%) at 
4°C and incubated with saturating concentrations (10 μg/ml) of a goat F(ab´)2 anti-
mouse immunoglobulin (goat anti-mouse, GAM) fluorescein isothyocianate (FITC-
labeled) (Bechton and Dykinson, Sunnydale, CA, USA) for 20 minutes at 4°C. After 
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incubation, the cells were washed (once), suspended again in 500 µl PBS and cell 
associated fluorescence was analyzed by a flow cytometer (FacsCanto, BD 
Biosciences). The percentage of positive cells and the mean fluorescence intensity 
(MFI) values were considered in evaluating antigen level of expression. 
mRNA EXTRACTION 
Total RNA was extracted from the clones that produce the anti-mesothelin antibody. 
Life Technologies protocol was used as follows: 
1) homogenization: 5x106 cells of the anti-mesothelin hybridoma were collected by 
centrifugation (5 minutes, 150 x g, 5°C) and likewise washed twice in 
physiologic solution (NaCl 0.9%). Then, the cell pellet was homogenized by 
resuspension in 1 ml TRizol Reagent (Life Technologies, Gibco BRL).  
2) phase separation: The homogenized sample was incubated for 5 minutes at 15 
at 30°C to allow the complete dissociation of nucleoprotein complexes. 0.2 ml 
of chloroform was added for 1 ml of TRizol Reagent. The tube was shaken 
vigorously by hand for 15 seconds and incubated at 15°C to 30°C for 2 to 3 
minutes. The sample was centrifuged at no more than 12000 x g for 15 minutes 
at 2°C to 8°C. Following centrifugation, the mixture was separated into a lower 
red phenol-chloroform phase, an interphase, and a colorless upper aqueous 
phase. RNA remained exclusively in the aqueous phase whose volume is about 
60% of the volume of TRizol Reagent used for homogenization. 
3)  RNA precipitation: the aqueous phase was transferred to a fresh tube (you can 
save the organic phase if isolation of DNA or protein is desired). The RNA was 
precipitated from the aqueous phase by mixing it with isopropyl alcohol. 0.5 ml 
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of isopropyl alcohol for 1 ml of TRizol Reagent used for the initial 
homogenization was added. The sample was incubated at 15°C to 30°C for 10 
minutes and centrifuged at no more than 12000 x g for 10 minutes at 2°C to 8°C. 
The precipitated RNA, often invisible before centrifugation, forms a gel-like 
pellet on the side and bottom of the tube. 
4) RNA wash: the supernatant was removed. The RNA pellet was washed once 
with 75% ethanol (1 ml 75% ethanol for 1 ml of TRizol Reagent used for initial 
homogenization). The sample was mixed by vortexing and centrifuged at no 
more than 7500 x g for 5 minutes at 2°C to 8°C. 
5) Redissolving the RNA : At the end of the procedure, the RNA pellet was briefly 
dried (air-dry or vacuum-dry for 5-10 minutes). It is important not to let the 
RNA pellet dry completely as this will greatly decrease its solubility. The RNA 
pellet was dissolved in RNase-free water (25 µl of H2O DEPC) and was 
quantified by spectrophotometer (1 unit at OD260 corresponds to an RNA 
concentration of 40μg/ml), reading the absorbance at 260 nm and 280 nm. The 
isolated RNA has an A260/280 ratio (that is the index of purity of the extract) of 
1.6 - 1.8 when diluted into distilled water. 
RETROTRANSCRIPTION AND cDNA SYNTHESIS 
The reaction of retrotranscription required a polymerase named retrotranscriptase that 
synthesizes a complementary DNA (cDNA) strand from single-stranded RNA. 
Retrotranscription to cDNA is obtained using SuperScript II
TM
 RT retrotranscriptase 
(reverse transcriptase kit, invitrogen) following the manufacturer‘s instructions (Table 
5): 
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COMPONENTS VOLUME 
Total RNA 5μl n μl 
10 mM dNTP mix 1 μl 
Random hexamer (50 ng/μl) 1-5 μl 
H2O DEPC qb 10 μl 
 
The mixture was incubated for 5 minutes at 65°C and then kept on ice. Consequently  
9 μl of the following reaction mixture were added (Table 6): 
COMPONENTS VOLUME 
10 X RT buffer 2 μl 
25 mM MgCl2 4 μl 
0.1 M DTT 2 μl 
RNasi OUT (RNasi inhibitors) 1 μl 
 
The reaction was incubated at 2 minutes at 25°C, after which 1 μl of SuperScriptTM  II 
RT was added. Using a thermocycler, the reaction is then incubated for 10 minutes at 
25°C, followed by 50 minutes at 42°C and finally 15 minutes at 70°C. The reaction was 
added with 1 μl of RNasi H and the same one was incubated for 20 minutes at 37°C. 
RNasi H was added to degrade hybrid RNA strand with DNA that generated during the 
retrotranscription process. 
 
 
 
 
Chapter IV (material and methods) 
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POLYMERASE CHAIN REACTION (PCR) 
The cDNA of the anti-mesothelin hybridoma was amplified by PCR to evaluate its 
functionality. The amplification was performed with a couple of specific primers 
(oligonucleotide). The general conditions used for the amplification were (Table 7): 
95°C 4 minutes   
95°C 1 minute  
30 cycles 56°C 1 minute 
72°C 1 minute 
72°C 7 minutes  
4°C end cycle  
 
The following components were used for the reaction (Table 8): 
Components Volume 
Primer S15 For 10 pMoli/μl 1 μl 
Primer S15 Rev 10 pMoli/μl 1 μl 
Gold Buffer 10 X no MgCl2 5 μl 
MgCl2 25 mM 3 μl 
DNTP 10 mM  1.25 μl 
Cdna 1-2 μl 
Taq Gold 5U/μl 2 μl 
H2O qb 50 μl 
  
The PCR (Polymerase Chain Reaction) product was a fragment of about 350 bp that 
was analyzed on 2% agarose gel. In order to select the appropriate couple of primers for 
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the amplification of fragments coding for the variable regions of heavy and light chains 
(VH and VK, respectively) of the anti-mesothelin hybridoma clone, a panel of 25 
forward and 4 reverse primers was considered for each variable domain (25 VH forward 
primers and 4 JH reverse primers; 25 VK forward primers and 4 JK reverse primers). 
Forward primers were designed considering highly conserved sequences at the 5´-end of 
DNA fragments for VH and VL domains from several families of murine 
immunoglobulins; reverse primers were instead inferred from J regions located at the 
3´-end of VH and VL DNA regions. Each forward primer was tested in a PCR reaction 
that includes a mix of the four reverse primers. Once the best forward primer has been 
thus selected, it is used in four individual PCR reactions, each one with a single reverse 
primer. As soon as the appropriate couple of primers has been selected (PCR 
amplificates were analyzed by agarose gel electrophoresis), the PCR products were 
sequenced. It was possible to check if the obtained sequences coded for VH and VL 
regions of antibodies, by sequences alignment studies that use BLAST program for 
bringing into line protein or nucleotide sequences.  
AGAROSE GEL ELECTROPHORESIS 
Agarose gel electrophoresis is the easiest and commonest way of separating and 
analyzing DNA. The purpose of the gel is to look the DNA, to quantify it or to isolate a 
particular band. The gel is constituted by agarose dissolved in TAE 1X (40 mM Tris-
Acetate, 1 mM EDTA in deionized H2O). The DNA is visualized in the gel by addition 
with ethidium bromide (end concentration of 0.5 µg/ml). This binds strongly to DNA by 
intercalating between the bases and its fluorescent meaning is due to the absorbance of 
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invisible UV light and the transmission of energy as visible orange light. The samples of 
analysis are added with loading buffer 6X that contains: 
- 1% SDS, that eliminates DNA-protein interactions, prevents appearance of 
additional bands due to annealing of DNA molecules with cohesive ends;  
- a dye to assess how "fast" your gel is running (0.05% Bromophenol Blue in 
deionized H2O); 
- a reagent to render your samples denser than the running buffer (so that the 
samples sink in the well) (50% Glycerol). 
Moreover, agarose gel electrophoresis provides the use of reference DNA size marker 
for the fragment size you expect to see in your sample lanes (the marker used is a 
mixture of chromatography-purified individual DNA fragments from 0.5 to 10 Kb, New 
England-Biolabs). The electrophoretic run is conducted to 70-90 Volts. 
MONOCLONAL ANTIBODIES PURIFICATION 
MAbs were purified from hybridoma supernatants using the affinity chromatography on 
sepharose-protein G column (resin sepharose-protein G, Pharmacia). The column was 
earlier equilibrated with bind buffer (PBS 1X ph 7.0). 
The column was washed extensively with bind buffer until obtaining a value of 
assorbance to the spectrophotometer (OD) lower than 0.05. 
The antibodies were eluted using glycine 0,1 M ph 3.0 with immediate neutralization 
into Tris 1 M ph 8.0. 
Material and Methods 
79 
 
The fractions containing the antibodies were identified through Comassie staining under 
denaturing conditions of SDS/PAGE. The fractions having the antibody protein were 
combined and dialysed against phosphate buffer solution (PBS). Finally, it was 
concentrated with Amicon Ultra-4 Centrifugal Filter Unit 10000 MWCO (Millipore) 
and the antibody concentration was determined by spectrophotometric reading of the 
assorbance at 280 nm (Gill and Von Hippel, 1989). Moreover, the protein concentration 
was carefully determined by BCA (bicinchoninic acid) Protein Assay. 
SDS PAGE (Sodium - Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis) 
Polyacrylamide gel electrophoresis (PAGE) of proteins is usually carried out using 
protein mixture that has been denatured by heating in the presence of an anionic 
detergent, sodium dodecylsulfate (SDS). SDS is a negatively charged molecule that 
becomes covalently coupled to proteins along their length upon exposure to heat; apart 
from denaturing the protein, this imparts also a negative charge in proportion to its 
length. Upon introduction of the protein sample to the gel and the application of a 
vertical electric field from the top of the gel to the bottom, proteins are repelled from the 
negative pole (the cathode) and migrate towards the positive pole (the anode). Due to 
the molecular sieving effect of the gel matrix, proteins within the mixture become 
resolved into discrete zone (bands) with the smallest proteins moving furthest through 
the gel. The proteins will have differentially migrated according to their size; smaller 
proteins will have travelled farther down the gel, while larger ones will have remained 
closer to the point of origin. Proteins may therefore be separated roughly according to 
their size (and thus their molecular weight). It is common to run molecular weight size 
markers of known molecular weight in a separate lane in the gel, in order to calibrate 
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the gel and determine the approximate molecular mass of unknown proteins by 
comparing the distance travelled relative to the marker. SDS PAGE was performed in 
Mini-Protean III Cell (BioRad) using running buffer 1X and maintaining a constant 
electric current of 90 Volts. 
BLUE COMASSIE STAINING 
The gel was soaked for about 20 minutes in a dye solution containing 50% methanol, 
10% acetic acid and 0,1% Comassie Brillant Blue R250. As the dye has stained the 
polyacrylamide gel as well as the protein, they needed to destain the gel in order to 
visualise the protein bands. Polyacrylamide gel was successfully destained using a 
solution of 30% methanol and 10% acetic acid solution for about 1 hour at room 
temperature in a stirrer. 
BCA (bicinchoninic acid assay) 
BCA is a biochemical assay for determining the total level of protein in a solution (0.5 
μg/mL to 1.5 mg/mL), similar to Lowry protein assay, Bradford protein assay or Biuret 
reagent. The total protein concentration is exhibited by a color change of the sample 
solution from green to purple in proportion to the protein concentration, which can then 
be measured using colorimetric techniques. 
The BCA assay relies primarily on two reactions: First, the peptide bonds in protein 
reduce Cu
2+
 ions from the cupric sulphate to Cu
+
 (a temperature dependent reaction). 
The amount of Cu
2+
 reduced is proportional to the amount of protein existing in the 
solution. Next, two molecules of bicinchoninic acid chelate with each Cu
+
 ion, forming 
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a purple-colored product that strongly absorbs light at a wavelength of 562 nm after 
incubation at 37°C for 20 minutes. The amount of protein presents in a solution can be 
quantified by measuring the absorption spectra and comparing it with protein solutions 
with known concentrations. 
mAb ANTI-MESOTHELIN/RTA CHEMICAL IMMUNOTOXIN 
Anti-mesothelin mAb was derivatized with the heterobifunctional cross-linker SPDP 
which reacted with its amino groups introducing a dithiopyridylgroup; after 
derivatization the mAb contained 2.53 sulphidryl group/mAb molecule, on average. 
Anti-mesothelin-SPDP molecule was conjugated via a reducible disulphide bond to the 
RTA toxin and the obtained anti-mesothelin/RTA IT was separated from unconjugated 
RTA by gel filtration chromatography on TSK 3000 SW column; a further purification 
from unconjugated mAb was achieved by an affinity chromatography passage on Affi 
Blue gel column.  
Fractions that contain the IT, as identified by SDS-PAGE and Western Blot analysis, 
were concentrated with centricon-10 and dialysed in PBS buffer. The IT concentration 
was determined evaluating absorbance at 280 nm and confirmed with BCA method. 
XTT cell viability assay 
To evaluate the IT killing activity dose response assay were performed on mesothelin 
positive and negative cells growing as a monolayer; the proliferation of IT treated and 
mock treated cells was measured as orange colored product‘s absorbance  
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XTT Cell Viability Assay provides a simple method for determination of live cell 
number using standard microplate absorbance readers. Determination of live cell 
number is often used to assess rate of cell proliferation and to screen cytotoxic agents. 
XTT is a tetrazolium derivative.  
Similar to MTT, XTT measures cell viability based on the activity of mitochondria 
enzymes in live cells that reduce XTT and are inactivated shortly after cell death. 
Unlike the water-insoluble formation produced from MTT, XTT is readily reduced to a 
highly water-soluble orange colored product [J. Infect. Dis. 172, 1153 (1995); J. 
Immunol. Methods 159, 81 (1993)], thus omitting the solubilization step required for the 
MTT assay. 
The amount of water-soluble product generated from XTT is proportional to the number 
of living cells in the sample and can be quantified by measuring absorbance at 
wavelength of 475 nm. 
Cells were plated into 96-well tissue culture plates. In general, cells should be seeded at 
densities between 5,000 and 10,000 cells per well since they will reach optimal 
population densities within 48 to 72 hours. 
The experiment was carried out by adding chemicals or biological agents. The final 
volume of tissue culture medium in each well should be 0.1mL, and the medium may 
contain up to 10% Fetal Bovine Serum. 
One bottle of XTT Solution and one vial of Activation Reagent were thawed and mixed 
for two 96-well plates (for one 96-well plate, mix 25μL Activation Reagent with 5mL 
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XTT Solution to derive activated XTT solution and save the rest of XTT Solution and 
Activation Reagent for later use). 
25 μL or 50 μL of the activated XTT solution was added to each well and the plate was 
incubated in an incubator for 2-24 hours (usually, 2-5 hours is sufficient).  
The plate was gently shaked to evenly distribute the dye in the wells. 
The absorbance of the samples was measured with a spectrophotometer (ELISA reader) 
at a wavelength of 450-500 nm. In order to measure reference absorbance (for non-
specific readings), use a wavelength of 630-690 nm. 
Results are expressed as percent of absorbance (proliferation) respect to mock treated 
control; to better evaluate the different killing activity we consider IC50, wich is the 
concentration of IT able to inhibit cellular proliferation of about 50%. 
.
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mRNA EXTRACTION OF THE Ag 
MESOTHELIN FROM 
TISSUE:Our group obtained a 
biopsy specimen by informed 
consensus from a patient 
affected with ovarian cancer.
PCR AMPLIFICATION OF 
MESOTHELIN-SPECIFIC cDNA : 
The mRNA was reverse-
transcribed and the cDNA
obtained was amplified by PCR.
RECOMBINANT MESOTHELIN 
PRODUCTION: The mesothelin-
specific cDNA was subcloned
into a prokaryotic expression 
vector (pET30a) and was 
transfected into bacteria E. Coli
strain BL21 DE3.
MESOTHELIN EXPRESSION IN 
HEK293 TRANSFECTED CELLS: 
it was necessary to proceed 
with the transfection of 
HEK293 cells with a cDNA from 
the human mesothelin to 
obtain cell line overexpressing
the antigen of interest.
BALB/c IMMUNIZATION : -
*Immunization: HEK293-
mesothelin  cells membranes. 
*Boosters : OVCAR-3 cells 
membranes, recombinant 
mesothelin and cells 
membranes of HEK293-
mesothelin .
PREPARING SPLENOCYTES FOR 
FUSION: The mouse was 
sacrificed and the spleen was 
removed.
PREPARING MYELOMA CELLS 
FOR FUSION: The myeloma 
cells were grown rapidly and 
healthy before the fusion.
SPLENOCYTES AND MYELOMA 
CELLS FUSION: The splenocytes
taken from immunized mice 
were fused with murine
myeloma following Kohler and 
Milstein protocol.
GROWTH OF HYBRIDOMAS:
ISOLATION MONOCLONAL 
HYBRIDOMA: The single 
polyclonal hybridoma was 
cloned by limiting dilution 
analysis technique .Two clones 
were chosen: A and B
PRODUCTION OF SPECIFIC 
ANTIBODIES: Clones A and B 
demonstrate a similar trend  on 
HEK293-mesothelin  cells in 
flow cytometry assay and they 
had also the same sequences 
of the variable regions (VH and 
VL).
ADAPTATION OF THE CLONES 
IN HYBRIDOMED MEDIUM: It 
was necessary to expand and 
adapt the cells to growth in a 
medium without bovine 
immunoglobulins.
PURIFICATION AND 
CHARACTERIZATION OF THE 
mAb FROM HYBRIDOMA: The 
clones A and B have been 
expanded. Their purification 
was performed by affinity 
chromatography on a column 
of protein G. 
ELISA
mAb ANTI-
MESOTHELIN/RTA 
CHEMICAL 
IMMUNOTOXIN
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RESULTS 
TOTAL RNA EXTRACTION FROM AN OVARIAN CANCER TISSUE 
Mesothelin was cloned from a surgical biopsy specimen of a women suffering from 
ovarian cancer (tissue was obtained with informed consensus). This sample was 
processed according to the TRIzol Reagent protocol, based on the separation of nucleic 
acids RNA and DNA and the proteins. The aqueous phase containing total RNA was 
washed, precipited with 75% ethanol to obtain an total RNA pellet and subsequently 
resuspended in DEPC water. The quality and concentration of RNA were evaluated by a 
spectrophotometer measuring the absorbance ratio 260/280 nm. 
RT-PCR END PCR AMPLIFICATION OF MESOTHELIN-SPECIFIC cDNA  
Total RNA was reverse-transcribed using random examer primers and the obtained 
cDNA was amplified by PCR using specific primers allowing amplification and cloning 
of mesothelin cDNA. The amplification reaction was subjected to agarose gel 
electrophoresis (Figure 13) which permitted us the identification of the amplified 
mesothelin cDNA according to its size (approximately 1,900 bp). 
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Fig. 13 The band obtained by PCR amplification of the mesothelin cDNA. The agarose gel run shows 
that the PCR product is about 1,900 bp. 
 
RECOMBINANT MESOTHELIN PRODUCTION  
The mesothelin cDNA was subcloned into a prokaryotic expression vector (pET30a) 
and then transfected into bacteria E. Coli strain BL21 DE3. After induction overnight, 
bacteria were diluted in fresh medium and grew in 1 L of LB medium with kanamycin 
until a spectrophotometric absorbance of OD 0.8 at 600 nm. Then they were inducted 
with IPTG for 3 hours at 30° C. The bacterial cells were afterwards lysed in buffer IB 
containing lysozyme, DNase I, PMSF and complete protease inhibitor (Roche); to 
improve bacteria lysis the mixture was subjected to repeated sonication cycles. The 
sonication process provides mechanical breaking of the cells whereas the buffer IB acts 
osmotic lysis of the membrane; the presence of protease inhibitors preserves our 
recombinat mesothelin from degradation. After the centrifugation of the lysis product 
and the elimination of the supernatant, we proceeded with the solubilization of the 
inclusion bodies pellet to obtain mesothelin. In previus experiments we had confirmed 
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that the recombinat Mesothelin was accumulated during bacterial growth in the 
inclusion bodies. 
In order to create new anti-mesothelin antibodies recognizing the native isoform of this 
human tumor antigen for immunotherapetical purposes, it was necessary to develop a 
refolding protocol. The refolding process was performed by sequential dialysis steps in 
different buffer solutions. We eliminated progressively the sodium lauryl sulfate 
(denaturant reagent) and than DTT reagent in order to slowly refolding  the protein. The 
dialysis protocol that has proven to show a very low level of aggregation products, took 
advantage from a series of buffers based on Tris-HCl; the last buffer provided the 
addition of arginine and glutathione (reduced and oxidized). Glutathione performed the 
refolding of the protein, whereas arginine protected it from potential reaggregation. The 
identification of Mesothelin produced in our baterial system was carried out by western 
blot (WB) developed with the commercial anti-mesothelin mAb K1 (Figure 14). The 
protein purification was performed by affinity chromatography using the affinity of 
imidazole rings of recombinant mesothelin poly-histidine tail for Ni-NTA resin. Once 
the chromatographic column was loaded with the refolded protein solution and some 
washing steps were performed , Mesothelin was eluted with a solution containing a high 
concentration of imidazole, which competes with the protein molecules for the binding 
to the resin. Elution fractions were analyzed by spectrophotometric reading and run on 
polyacrylamide gels in order to determine the protein concentration and its purity. 
Recombinant mesothelin was used for mice immunizations and ELISA assays. 
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Fig. 14 Western blot with anti-mesothelin mAb K1 of BL21 DE3 bacteria lysate. 1) not induced 
cytoplasm 2) induced cytoplasm 3) not induced inclusion bodies 4) induced inclusion bodies 5) lysate of 
ovarian carcinoma (positive control). 
MESOTHELIN TRANSFECTED HUMAN HEK293 CELLS 
Above all, it was necessary to proceed with the transfection of human HEK293 cells 
with mesothelin cDNA to obtain a cell line overexpressing the antigen of interest. 
This new cell line was used for both immunization protocols and functional 
characterization of the synthesized mAbs by flow cytometry.  
HEK293 cells were stably transfected with the plasmid pcDNA3.1-mesothelin, 
previously linearized. The transfection was performed with Lipofectamine 2000 
following manufacturer‘s protocol (Invitrogen). 
pcDNA3.1 vector contains neomycin resistance gene. The selection and maintenance of 
the transfected cells were performed by using antibiotic G418 that only permits the 
survival of transfected cells with neomycin resistance genes.  
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Mesothelin expression on the surface of the transfected HEK293 cells was confirmed by 
flow cytometry using a commercially available anti-mesothelin mAb K1. 
FACS analysis was performed on HEK293-mesothelin cells and HEK293 wt cells as 
negative control.  
The transfection efficiency was analyzed considering two parameters: 
Mean Fluorescence Intensity (MFI) and the percentage of cells depicted in the channel 
select as positive.. 
As summarized in Table 9, mAb K1 showed a MFI value of 8,650 on HEK293-
mesothelin cells compared to a MFI value of 152 on HEK293 wt cells. Irrelevant MFI 
values were detected with isotype matched control Ab on the same cells (MFI 216 and 
MFI 213 respectively). 
The positive control Ab anti MHC-1 B912.1 showed an MFI value of 2,096 on 
HEK293-mesothelin cells and MFI value of 1,178 on HEK293 wt cells; Figure 15 
confirms that mAb K1 strongly stained HEK293-mesothelin cells whereas irrelevant 
staining was detected on HEK293 wt cells. 
 
 
 
 
Results 
90 
 
 HEK293-mesothelin HEK293 wt 
Sample MFI % of positive 
cells 
MFI % of positive 
cells 
Negative 
control 
216 2.4 213 0.7 
Positive 
control 
2,096 93.4 1,178 85.2 
Ab K1 8,650 88.3 152 1.4 
Table 9 Data obtained by flow cytometer analysis performed on HEK293-mesothelin and HEK293 wt 
cell lines using anti-mesothelin mAb K1 compared to isotype matched Ig negative control (Ab Goat Anti 
Mouse – FITC - Ab GAM-FITC) and positive control (Ab anti MHC-1 B912.1). 
 
   
 
Fig. 15 FACS analysis of the HEK293-mesothelin cells (A, B, C) and HEK293 wt cells (D, E, F). A, D) 
mAb K1; B, E) Ab anti MHC-1 B912.1; C, F) Ab GAM-FITC. 
A B C 
E D F 
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BALB/c IMMUNIZATION WITH MESOTHELIN EXPRESSING CELL 
MEMBRANES 
BALB/c mice were immunized as described in chapter ―material and method‖. The anti-
mesothelin Ab responses were primarily monitored in mice immunized sera by flow 
cytometry analysis on HEK293-mesothelin and HEK293 wt cell lines. Serum of non-
immunized mice representes the negative control. As shown in Table 10, MFI value of 
one out of three serum of immunized mice was 14,779 on HEK293-mesothelin cells 
compared to a MFI value of 703 on HEK293 wt cells. Moreover, MFI value of the non-
immunized mouse serum shows nearly the same MFI value on both HEK293-
mesothelin and on HEK293 wt cells (MFI of about 183). The immunized mouse, whose 
serum showed the highest anti mesothelin Ab titer, received a booster immunization by 
an intraperitoneal injection of HEK293-mesothelin cell membranes and an intravenous 
injection of the mesothelin recombinant protein, at days -3, -2, -1 from the splenectomy. 
Figure 16 confirms that immunized mouse serum strongly stained HEK293-mesothelin 
cells, whereas poor staining was detected on HEK293 wt cells; it is important to remind 
that antiserum generated in this way also contained considerable amounts of other 
antibodies directed against a variety of membrane antigenic determinants (this 
antiserum was said to be polyclonal). 
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Table 10 Mean Fluorescence Intensity (MFI) values obtained by flow cytometry analyzing an immunized 
mouse serum and a non-immunized mouse serum on both HEK293-mesothelin and HEK293 wt cells. 
 
     
 
Fig. FACS analysis performed on HEK293-mesothelin cells (A, B, C, D) and HEK293 wt cells (E, F, G, 
H). A, E) immunized mouse serum; B, F) mAb K1; C, G) Ab GAM-FITC; D, H) non-immunized 
mouse serum. 
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Based on these data, Hybridomas were prepared by the technique of hybridization of an 
immortal myeloma cell line with an antibody-producing B cell, as developed by Kohler 
and Milstein in the late 1970s. 
GENERATION AND GROWTH OF HYBRIDOMAS 
The splenocytes taken from an immunized mouse spleen were fused with a murine 
myeloma and the cell suspension obtained was then seeded in two 24 wells-plates. 
During the two weeks following the fusion, hybridoma cell growth was monitored by 
evaluation with a microscope. The supernatants of polyclonal hybridomas were 
analyzed by flow cytometry to detect the presence of antibodies recognizing the antigen 
of interest. Assays were performed on antigen positive cells (HEK293-mesothelin) and 
antigen-negative cells (HEK293 wt) in order to confirm the specificity of the 
recognition. Only one out of the 48 analyzed hybridoma supernatants stained 
mesothelin positive cells in flow cytometry whereas irrelevant staining was detected for 
the other hybridomas (Figure 17). Supernatants were also analyzed by ELISA (Enzime 
Linked Immunosorbent Assay); all clones recognized recombinant mesothelin because, 
we suppose, it was more immunogenic than the native form of the protein (data not 
shown). 
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Fig. 17 FACS analysis carried out on HEK293-mesothelin cells (A, B, C) and on HEK293 wt cells (D, E, 
F) to 94ssess superantants of polyclonal hybridomas. The negative control is represented by Ab goat anti-
mouse (A, D) and the positive control is represented by Ab anti MHC-1 B912.1 (B, E); supernatants of  
the polyclonal hybridoma of interest (C, F). 
The positive polyclonal hybridoma supernatant (Figure 17) was analyzed in flow 
cytometry more than one time with intervals of about 8 days to verify that the antibody 
production and the specificity were stable over time (Table 11). 
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HEK293-mesothelin cells  MFI FITC % of positive cells 
Negative control 176 2.2 
First analysis 50,876 94.6 
Second analysis 38,991 93.2 
Third analysis 73,915 98.0 
Table 11 Values obtained by flow cytometric analysis of the single mesothelin positive polyclonal 
hybridoma assessed at intervals of 8 days on HEK293-mesothelin cells. 
The variability of the MFI between the second control and the third one is due to 
different Ag expression in transfected cells because the same behavior was also 
observed using the monoclonal Ab K1. 
The table shows that the hybridoma did not lose its ability to produce specific 
antibodies. 
FROM POLYCLONAL TO MONOCLONAL HYBRIDOMA 
The positive polyclonal hybridoma was then cloned by limiting dilution assay (LDA) in 
three 96-wells plates. During growth, some wells that showed to have more than one 
clone/well were removed. The individual clones were then expanded and the 
supernatant was analyzed in flow cytometry to assess the ability of cells to produce a 
specific monoclonal antibody recognizing the antigen of interest. 
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FACS analysis identified 34 positive clones. The assays were performed more than one 
time, on HEK293-mesothelin cells and HEK293 wt cells to check the stability of the 
antibody production by the clones themselves. Two clones were chosen: A and B 
(Figure 18), 
 
Fig. 18 FACS analysis of the clone A on HEK293-mesothelin cells (A, B, C) and HEK293 wt cells (D, E, 
F). Ab GAM-FITC was used as a negative control (A, D); Ab anti MHC-1 B912.1 (B, E) was used as a 
positive control to compare the binding properties of the clone A (C, F). The clone B showed a staining 
superimposable to that of clone A (data not shown). 
As summarized in Table 4, comparing MFI values of the supernatants with positive 
control MFI value, it appears that the reactivity on HEK293-mesothelin transfected cells 
is specific. By the contrast, irrelevant MFI value (comparable to negative control) was 
detected on HEK293 wt, thus indicating that the supernatants did not show non specific 
recognition (Table 12). 
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HEK293-mesothelin cells MFI % of positive cells 
Negative control 200 2.0 
Positive control 56,481 95.8 
Clone A 36,599 92.5 
Clone B 47,176 91.3 
Table 12 FACS analysis to evaluate anti-mesothelin antibodies produced by clone A and clone B 
supernatants. Data show MFI values and % of positive cells obtained on HEK293-mesothelin cells 
compared to MFI values obtained with the negative control (Ab GAM-FITC) and the positive control 
(mAb K1). 
HEK293 wt cells MFI % of positive cells 
Negative control 202 2,7 
Positive control 2,252 98.3 
Clone A 212 3.0 
Clone B 201 2.4 
Table 12 MFI values and % of positive cells obtained by flow cytometer analysis of clone A and clone B 
hybridoma supernatants on HEK293 wt cells. Data indicate that the supernatants contain antibodies that 
explicitly do not recognize specific antigen negative cells. Negative control, Ab GAM-FITC. Positive 
control, Ab anti MHC-1 B912.1. 
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The supernatants of these clones were further analyzed on cells constitutively 
expressing the mesothelin (OVCAR-3 cell line) (Table 13); this analysis was important 
to assess whether we produced Abs recognizing the constitutive form (or native form) 
of the antigen. Mesothelin is express with different glicosilation grade and refolding 
processes on tumor cells; for this reason, it‘s important to evaluate the ability of our Ab 
to recognize these modified form. Moreover, the clones were also assesses on different 
antigen negative cell lines to better evaluate the non specific binding, excluding the 
phenomena of cross-reactivity. Flow cytometry analysis were carried out on: 
- Mesothelin expressing cells OVCAR-3; 
- Mesothelin not expressing cells: C6, U937, A431, PC3, Jurkat; 
From these additional studies we have confirmed the ability of these antibodies to 
recognize the constitutive form (or native form) of the antigen and the specificity of the 
antibodies themselves. 
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The data were compared with the positive control mAb anti-mesothelin K1. 
OVCAR-3 cells MFI % of positive cells 
Negative control 246 6.4 
Positive control 3,259 90.2 
Clone A 1,430 72.4 
Clone B 2,695 88.1 
Table 13 FACS analysis to evaluate anti-mesothelin antibodies produced by clone A and clone B. Data 
show MFI values and % of positive cells obtained on OVCAR-3 cells. 
As shown in Table 6 the antibodies produced by clones A and B are able to recognize 
the antigen mesothelin expressed on the membranes of OVCAR-3 cells. The results 
shown in Table 14 summarize experiments performed on antigen negative cells; the 
MFI values obtained by clone A and clone B supernatants are comparable to MFI value 
of the negative control, demonstrating that no aspecific staining is detectable on antigen 
negative cells. 
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CELL 
LINE 
U937 Jurkat A431 C6 PC3 
SAMPLE MFI % of 
positive 
cells 
MFI % of 
positive 
cells 
MFI % of 
positive 
cells 
MFI % of 
positive 
cells 
MFI % of 
positive 
cells 
NEGATIVE 
CONTROL 
149 2.1 554 1.1 227 5.2 156 2.7 228 2.5 
CLONE A 168 2.2 152 0.4 245 7.0 182 3.7 247 4.8 
CLONE B 165 2.6 160 0.4 247 7.3 193 4.7 259 5.8 
Table 14 FACS analysis to evaluate anti-mesothelin antibodies produced by clone A and clone B. Data 
show MFI values and % of positive cells obtained on different antigen (mesothelin) negative cell lines 
compared to MFI values obtained with the negative control. 
Taken together these results suggest that antibodies produced by clones A and B are 
able to recognize the antigen mesothelin in the native and recombinant form. 
GROWTH OF THE CLONES IN HYBRIDOMED MEDIUM 
It was necessary to expand and adapt the cells to growth in a medium without FCS and 
therefore without bovine immunoglobulins: Hybridomed Medium; this allows to purify 
the antibody without contamination by other Abs of bovine origin. The adaptation has 
been conducted gradually moving from a HAT medium 20% FCS to a HT medium 20% 
FCS and then RPMI 20% FCS until to RPMI 10% FCS and finally to the medium 
Hybridomed. 
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During the adaptation phase, the secretion and the functionality of the produced Abs 
were always monitored by flow cytometry. 
PURIFICATION AND CHARACTERIZATION OF THE NEW mAbs 
The clones A and B that produce the anti-mesothelin antibodies have been expanded to 
obtain a sufficient amount for purification. Their purification from the hybridoma 
growth medium was performed by affinity chromatography on a protein G column. 
Since the two clones A and B produced the same Ab, we wanted to investigate whether 
one of the two clones was more productive than the other one. 
The purified antibodies from the two clones were quantified by photometric absorbance 
at 280 nm and by BCA assay and the results obtained were comparable. From 250 ml of 
culture medium of each of the two clones 3mg of anti-mesothelin Ab were 
approximately obtained. From now, we will only consider data concerning mAbs 
produced by clone A hybridoma because, after sequencing VH and Vk regions, we 
disclosed an absolute identity among this two mAbs (A and B). The purity of the 
antibody was then analyzed by SDS-PAGE (Figure 19). 
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Fig. 19 10% polyacrylamide gel and Coomassie staining of the Ab anti-mesothelin obtained by affinity 
column purification. 
Polyacrylamide gel shows a single band at about 150 kDa, demonstrating the purity of 
our preparation. 
The purified antibody was then analyzed in flow cytometry to evaluate if it maintained 
the ability to bind specifically its target antigen. The analysis was performed on 
HEK293 wt, HEK293-mesothelin (data not shown) and OVCAR-3 cell lines. 
As shown in Table 8, the Ab maintains the ability to recognize specifically the antigen. 
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OVCAR-3 cells MFI % of positive cells 
Negative control 148 0.6 
Positive control 56,575 97.9 
Clone A purified 38,135 98.5 
Table 15: MFI values and % of positive cells obtained by flow cytometric analysis conducted to test the 
specificity of recognition of the anti-mesothelin mAb on OVCAR-3 cells after the purification.  
The Ab was then characterized by assessing the affinity by binding studies on HEK293-
mesothelin cells. Scalar concentrations of the Ab of interest and Ab K1 were used for 
the assay. Subsequently, the samples were incubated with secondary antibody Goat Anti 
Mouse FITC at a saturating concentration and analyzed by flow cytometry. 
Figure 20 shows that decreased concentrations of the Ab in object correspond to 
decreased binding percentage. The picture describes the results of the cytofluorimetric 
analysis, where MFI values were revised according to the maximum MFI value which 
was assigned to the 100% saturation of antigenic sites (mesothelin present on the cell 
membrane of HEK293-mesothelin). 
The results are described by a sigmoid curve that allows the comparison of the two 
antibodies binding capacity. Our ―home-made ― anti-mesothelin mAb has better affinity 
compared to the commercial one K1. Our ―home-made‖ anti-mesothelin mAb saturates 
at a concentration of about 9 nM, while mAb K1 requires slightly higher concentrations 
(18 nM). 
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Fig. 20 Binding curves. FACS analysis about the saturation of mesothelin existing on the membrane of 
HEK293 transfected cells in the presence of scalar concentrations of Ab K1 and ―home-made‖ anti 
mesothelin mAb produced by hybridoma technology. Data revised according to the maximum MFI value 
which was assigned to the 100% saturation of antigenic sites. 
According to the results showing high specificity and high affinity, we decided to 
identify the sequences of the antibody variable regions (VH and VL regions) to create 
antibody fragments (scFv format) from the whole anti-mesothelin mAb. Total RNA was 
purified from hybridoma cells secreting monoclonal antibodies and VH and VL regions 
were obtained by reverse transcription. Since mouse Ig employs preferentially k light 
chains (1:10 ratio λ/k), we used for VL amplification degenerated primers for Vk and Jk 
domains only. Primers for this first amplification were designed to match the leader 
regions of the VH and Vk chains and both constant regions of together heavy and light 
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chains. 25 PCR reactions were carried out for each V chain combining 25 different VH 
or Vk murine domain forward primers with a mix of four JH or Jk corresponding 
reverse ones as showed in Figure 10. The products of VH and Vk amplification can be 
visualized on a 2% agarose gel and are nearly 350 bp long; 7 out of 25 primers amplify 
the Vk and 13 out of 25 the VH; positive controls were obtained by Vk and VH 
sequences amplification of an anti-human CD3 murine hybridoma; in the picture above 
we can observe that because of the primer sequences degeneration, we have 
amplification products from several V-primers. Among them, according to band 
intensity and low amplification background, we have chosen one VH (lane 28) and one 
Vk (lane 3) forward primers. 
 
Fig. 21 PCR products obtained by PCR amplification of the anti-mesothelin hybridoma cDNA with 25 
forward primers for Vk region (blue) and 25 forward primers for VH region (red). 
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At this point, it was important to test the ―joining‖ (J) primers separately in order to 
identify JH and Jk ones leading to the best matching pair for heavy and light chain 
amplifications. V genes obtained by PCR were sequenced using the same forward and 
reverse primers as for PCR reactions. The sequences of the variable regions of heavy 
and light chains of anti-mesothelin Abs produced by the two hybridomas are shown 
below. The Complementary Determining Region [CDRs (CDR1, CDR2 and CDR3)] 
represented by underlined regions have been edited because of patent restriction. 
The sequence of the variable heavy chain VH of the mAb clone A is the following: 
ELEGPELSCVASGFTFXXXXXXWVRQTPEKRLEWVXXXXXXXXXXXXXXXX
XRFTISRDNARNILFLQMSSLRSEDTAMFYCARXXXXXXXXXXWGAAGTTVT
XLLK. 
The sequence of the variable light chain of the mAb clone A Vk is the following: 
LLGQRATISYXXXXXXXXXXXXXXXWNQQKPPGQPPRLLIYXXXXXXXGVPA
RFSGSGSGTDFTLLNIHPVEEEDAATYYCXXXXXXXXXEGGPSWK. 
The sequences of the variable regions of mAb clone B were the same of mAb clone A. 
Based on a comparison method of the sequences described by Kabat and Wu (1991), it 
was evident that VH and Vk aminoacidic sequences of our ―home-made‖ mAb anti-
mesothelin corresponded to the VH and Vk aminoacidic sequences of ―standard‖ 
antibody. 
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To confirm this, clone A shown the aminoacidic sequence ASGFTF before of the 
heavy chain CDR1 region, whereas the aminoacidic sequence CAR was before of the 
CDR3 region.  
Moreover, the aminoacidic sequence WNQQKP after the light chain CDR1 region and 
the aminoacidic sequence DAATYYC before of the CDR3 region described this 
correspondence. 
Taken together, these results suggest that mAbs produced from the clone A and B are 
identical, because they are characterized by the same variable light and heavy chains. 
The evidence of this similarity between antibodies produced by clone A and clone B 
comes from the complementarity-determining regions CDR1, CDR2, CDR3 of these 
mAbs that are able to bind the same epitope and with the same affinity. 
SYNTHESIS OF THE ANTI MESOTHELIN IT: mAb –spdp-nRTA 
The whole mAb was chemically linked to ricin A chain toxin (RTA) in order to create 
an IT anti Mesothelin: mAb–spdp-nRTA. The IT killing efficacy will be studied on 
mesothelin positive and mesothelin negative cells. Chemical linked IT was synthesized 
by conjugation of RTA toxin to the mAb anti mesothelin via a disulfide bond, using the 
cross-linker SPDP molecule. After reducing cysteines on RTA protein by DTT and the 
derivatization of the mAb with SPDP, the binding reaction of these two reagents took 
place for about 2 days at 4°C; the obtained IT was then purified from unconjugated 
reagents by a first step of gel filtration chromatography. The chromatogram in Figure 8 
displays a purification run obtained through a Bio-Rad FPLC apparatus. A second 
chromatographic purification on an Affi-Blue gel column allowed us to remove the 
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unconjugated mAbs. It is mandatory to eliminate these free mAbs, because they are able 
to compete with IT for the binding to the target antigen; this competition could mask the 
real killing efficacy of the IT in the cells assay (Figure 22). 
Fig. 22 Chromatogram of a purification run of the IT on gel filtration column. 
“IN VITRO” IMMUNOTOXIN EFFICACY 
In order to evaluate the cytotoxic effect of anti-mesothelin ITs, we measured the 
proliferation of mesothelin positive and mesothelin negative cells once treated in a 
dose-response assay with ITs and toxin alone. Cytotoxic effects were compared in terms 
of IC50, which defines the reagent concentration able to inhibit cell proliferation of 
about 50% respect with a mock treated control. Figure 23 describes the data obtained 
from a typical experiment performed on mesothelin positive cells. 
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Fig. 23 Dose-response curves obtained treating  HEK293-mesothelin cells with increasing concentration 
of molecules described in the picture. The cytotoxic efficacy, XTT assay, was measured considering the 
absorbance of water-soluble orange colored product after 36 hrs. Samples: IT – immunotoxin; nRTA,; 
RICIN. 
 
As illustrated in the Figure 23, chemical IT (anti-mesothelin mAb-spdp-nRTA) showed 
an high cytotoxic activity (0.03 nM) on HEK293-mesothelin cells after 36 hrs of 
incubation; the nRTA toxin used for the synthesis of the IT showed an IC50 of about 193 
nM on the same cells. As expected ricin alone showed the highest cytotoxic activity.  
The specificity of IT mediated killing was further investigated by comparing the 
cytotoxic effects on HEK293 wt cells after 36 hrs of incubation.  
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As illustrated in the Figures 24, chemical IT (anti-mesothelin mAb-spdp-nRTA) did not 
show cytotoxic activity on above-mentioned cells. In the same manner Ricin alone 
confirmed the highest cytotoxic activity on these cells. 
 
 
Fig. 24 Dose-response curves obtained treating HEK293 wt with increasing concentration of  molecules 
described in the picture. The cytotoxic efficacy was measured considering the absorbance of water-
soluble orange colored product after 36 hrs of incubation. IT – immunotoxin; nRTA anti-meso-nRTA; 
RICIN – ricina. 
 
The same assay was carry out on other mesothelin negative cell lines A431, PC3, 
JURKAT and CEM. Table 16 showed that chemical IT does not have cytotoxic activity 
on mesothelin negative cells confirming an high specificity of binding and recognition 
of its target antigen expressed on the cell surface. 
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Table 16 Dose-response data obtained treating mesothelin negative cells A431, JURKAT, PC3, CEM. 
The cytotoxic efficacy was measured considering the absorbance of water-soluble orange colored product 
after 36 hrs of incubation. IT- immunotoxin; TOXIN - anti-meso-nRTA; RICIN - ricina. 
 
The cytotoxic activity was also investigated on positive (HEK293-mesothelin) and 
negative cell lines (HEK293 wt, A431, PC3) after 72 hrs of incubation with 
immunotoxin (IT), toxin (nRTA) and Ricin to detect if chemical IT increases the 
specific toxicity on a more long time of its permanence on cells. As illustrated in the 
table 17 chemical immunotoxin, maintained an high specific cytotoxic killing (0.09 nM) 
superimposable to that of 36 hrs of incubation. 
Table 17 Dose-response data obtained treating mesothelin positive cells (HEK 293-mesothelin) and 
mesothelin negative cells (HEK293 wt, A431, PC3). The cytotoxic efficacy was measured considering 
the absorbance of water-soluble orange colored product after 72 hrs of incubation. IT- immunotoxin; 
TOXIN - anti-meso-nRTA; RICIN - ricina. 
 
We can conclude that the conjugation of anti-mesothelin mAb to the toxins substantially 
potentiates the toxicity of RTA against mesothelin positive cells. 
As a further proof of specificity, we also incubated, in a classic cytotoxic assay, 
HEK293-mesothelin cells with a fixed concentration of anti-mesothelin mAb–spdp-
RTA IT (0,03 nM) in the presence of increasing molar excess of the unconjugated anti-
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mesothelin mAb (e.g. 10X, 100X, 1,000X), to displace chemical IT binding and 
specifically prevent cell intoxication. As illustrated in Figure 25 the cytotoxic effect of 
IT on HEK293-mesothelin cells was completely removed using a 1,000 molar excess of 
anti-mesothelin mAb; this observation supports the concept of an antibody-mediated 
and specific cytotoxicity of our IT. 
 
Fig. 25 The cytotoxic effect of the IT on HEK293-mesothelin cells was decreased using increasing 
concentration of anti-mesothelin mAb. 
.
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DISCUSSION 
Cancer is the second leading cause of human death next to coronary disease. 
Worldwide, millions of people die from cancer every year and deaths generally are on 
the rise. Conventional therapies, like surgery, radiotherapy and chemotherapy, are not 
always sufficient to eliminate the tumor and the possible metastases; moreover these 
therapies are responsible of many side effects. For this reason there is an urgent need for 
new treatments strategies, the most promising one is probably immunotherapy.  
In this context, the mesothelin is a membrane glycoprotein of about 40 kDa, whose 
expression at physiologic tissues is limited to the mesothelial cells of serosa (pleura, 
pericardium and peritoneum). The protein is instead overexpressed in different tumoral 
histotypes, in particular in ovarian, pancreatic and lung carcinoma so as in all 
mesothelioma. A restricted distribution of the mesothelin through physiologic tissues 
and, in the opposite, an overexpression in many neoplastic histotypes make that protein 
be a promising target for imaging procedures and for the specific tumor treatments. 
Moreover, in many patients affected with ovarian carcinoma or mesothelioma, the 
mesothelin is shedded in the serum, supposing a potential usage as a biomarker. 
Nowadays, there are various studies aiming at finding antibodies that are specific for the 
mesothelin and some molecules have just entered in clinical trials: CAT-5001 
(recombinant immunotoxin) and MORAb-009 (chimerical antibody). Since both 
molecules contain some murine portions, once given to patients they can determine the 
development of HAMA (Human Anti-Mouse Antibody) reactions; the necessity to 
create some full human Abs arises from that. In this contest, an article by the Ho M. and 
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colleagues has recently (May 2011) been published, where a complete human antibody 
HN1 (scFv) directed to the mesothelin is presented (Ho M. et al., 2011). This antibody 
acts by sequestring mesothelin and so by preventing its binding to CA125 protein on 
cancer cells.In addition, the HN1 IgG kills cancer cells with very strong antibody 
dependent cell mediated cytotoxicity (ADCC). Moreover, there is in the same study 
some information about the creation of an immunotoxin composed by HN1 fused with 
PE38 toxin ( the truncated portion of the exotoxin A of Pseudomonas Aeruginosa). This 
immunotoxin proved to be able to selectively eliminate tumor cells overexpressing the 
mesothelin with high cytotoxic activity. 
Because commercial mAb to mesothelin is not already available, due to patent 
restriction the aim of the my thesis was to produce a murine monoclonal antibody 
specific for the mesothelin to eventual usage in diagnosis and therapy. 
Once obtained the specific-mesothelin c-DNA has been amplified by PCR and inserted 
inside vectors for expression in prokaryote and eukaryote. Then, the cloned sequence 
functionality has been evaluated through the production, respectively, of the 
recombinant protein in bacteria, and through the creation of transfected cell lines. The 
recombinant protein has been shaped by transforming a bacteria strain of E. Coli, BL21 
DE3 with the pET30a vector; then, the protein has been purified on a chromatographic 
column by affinity. Inclusion bodies have been previously lysed, while the protein had 
been refolded before purifying. In the course of the refolding the protein showed a high 
tendency to aggregate, especially in saline solutions; the remedy to that was developing 
a refolding protocols based on low salt concentration buffers. Moreover, the protein has 
been expressed on HEK293 cell membrane through transfection with pcDNA3.1-
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mesothelin vector. FACS analyses demonstrated that the transfection took place 
successfully (MFI = 8,650 for transfected cells e MFI = 216 for negative control). 
The recombinant protein and the transfected cells overexpressing the antigen of interest 
were fundamental instruments for the execution of the project. In fact, they were useful 
reagents for the screening of the hybridomas obtained by the fusion after mice 
immunization, because we need simple, fast and relatively low cost assays to analyze 
the mAb specificity. In our case, the assays we decided to use were ELISA assays and 
flow cytometry. 
Then, reagents were essential to perform the mouse immunization protocols; in fact, in 
our laboratory the best results have been obtained using cell membranes of cells 
overexpressing the antigen of interest during the first phases (see i.p. injections, material 
and methods). These stimulate the antigenic response and in the specific case of 
membrane proteins, they tend to maintain their native form also dimer, allowing the 
generation of Abs able to identify the target protein on cells and, therefore, to get Abs 
for applications in diagnostic and thereutical procedures. The recombinant protein, on 
the contrary, has been used for boosters (see i.v. injections, material and methods) 
before the fusion, due of its solubility.  
Subsequently, polyclonal hybridomas have been obtained through Kohler and Milstein 
technique. Balb/c mice were immunized by injection of membranes of cell lines 
expressing the antigen in the native (OVCAR-3) or transfected (HEK293-mesothelin) 
form, and of the recombinant protein produced in the bacteria. 
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The flow cytometer analysis allowed us to check the presence of anti-mesothelin 
antibodies in the sera of immunized mice. The supernatants of 48 polyclonal 
hybridomas obtained after the fusion were tested by FACS to evaluate the presence of 
Abs specific for the mesothelin. The analysis was done on HEK293 wt cells and 
HEK293-mesothelin and brought to the identification of a unique out of 48 positive 
polyclonal hybridoma; in fact, the others showed a value of MFI on HEK293-
mesothelin which was comparable with the value of MFI obtained with HEK293 wt 
cells. The same analyses was conducted by ELISA assay where all the hybridomas were 
positive; that result depended from an antibody response to the Ag recombinant that 
probably expressed more immune-dominant epitopes than the initial shape. 
A prior fusion obtained after animal immunization with cell membranes (i.p. injected) 
and recombinant protein (i.v. and i.p. injected instead that only i.v. ) generated only 
hybridomas that recognized the recombinant mesothelin (data not showed). In our case 
it is therefore very important the choice of the immunization protocol, because the 
antibody response developed against recombinant protein does not allow to obtain with 
a good frequency Abs that also recognize the proper folding of the protein. 
The only positive polyclonal hybridoma has been analyzed in three flow cytometer 
assays at a interval of eight days and it proved that the hybridoma does not lose the 
ability to produce Abs specific. At this point, the specific polyclonal hybridoma has 
been cloned by the Limiting Dilution Analyses technique and the supernatants of the 
monoclonal hybridomas have been analyzed by FACS on HEK293 wt cells and 
HEK293-mesothelin cells. 34 clones resulted positive and two were chosen among them 
for further analyses: clones A and B. Clones A and B were further tested by FACS 
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analysis on cells expressing the mesothelin in the native form (OVCAR-3) and on a 
panel of antigen negative cell lines: C6, U937, A431, PC3, Jurkat. This last analyses 
demonstrated that clones A and B produce specific antibodies against mesothelin and 
that those antibodies are able to recognize the antigen also on cell lines which express it 
constitutively. The lack of cross-reactions on the mesothelin-negative cell lines has been 
proved. 
For additional characterization studies, we needed to produce high amounts of 
monoclonal antibodies of interest and purify them. So, it was necessary to adapt clones 
to the growth in a medium devoid of FCS: Hybridomed. The use of that medium allows 
ultra-pure preparations of the Ab of interest excluding possible contaminations by 
bovine immunoglobulin. The antibodies were purified on a chromatographic column by 
affinity and were quantified by absorbance evaluation at 280 nm using a 
spectrophotometer and by BCA assay. From about 250 ml of culture medium of each 
clone 3 mg of Ab-anti-mesothelin were obtained. The purified Ab was farther tested by 
flow cytometry to check that after purification it would have maintained the ability to 
specifically recognize mesothelin; the antibodies were eluted from the columns of 
affinity with low pH buffers, conditions that in some cases can inactivate their 
functionality. 
At this point of the project it was interesting to verify if the antibodies produced by the 
two clones were identical; this could be partly proven, studying the capability of both 
biotinylated Ab of clones to displacement each other in the antigen binding (data not 
shown). To have a sure response we used the technology of recombinant DNA 
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identifying the variable regions (VH and VL) of the two Abs through PCR and 
sequence. 
Sequence brought to the conclusion that the two cell clones A and B produce the same 
Ab because they contain the same light and heavy variable regions, so they recognize 
the same epitope and with the same affinity. 
Finally, the affinity of Ab for the mesothelin was evaluated by binding studies carried 
out on HEK-293-mesothelin cells. Scalar concentrations of Ab of interest and of 
commercially available mAb K1 were used for the assay. Then, the samples were 
incubated with the secondary Ab Goat Anti Mouse FITC at saturating concentrations 
and analyzed by flow cytometry. From that analysis, our Ab resulted to have a better 
affinity than the mAb K1; in fact, our Ab saturates the mesothelin molecules present on 
the membranes of the cells HEK293-mesothelin at a concentration of about 9 nM, while 
mAb K1 requires for slightly higher concentrations (18 nM). 
Next step will consist on testing on a wider panel of positive cells our Ab to confirm 
that it is able to recognize the antigen expressed constitutively on different cell lines.  
The good binding properties in its native form of our ―home-made‖anti-mesothelin 
mAb, represented a good prerequisite to synthesize immunoconjugates for either 
diagnostic and therapeutic applications. We here produced chemical ITs (anti-
mesothelin mAb–spdp-nRTA) that showed powerful and specific cytotoxic efficacy 
against mesothelin-positive cells, even better than nRTA alone. The same chemical ITs 
did not show any cytotoxic effect against mesothelin-negative cells. 
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In the cytotoxic experiments anti-mesothelin mAb–spdp-RTA chemical IT don‘t have 
toxicity on mesothelin negative cells (IC50 values don‘t detectable); moreover chemical 
IT is 6,433 and 1744 fold more toxic than the nRTA alone on HEK293-mesothelin cells 
after 36 hrs and 72 hrs of incubation respectively. This large ―therapeutic windows‖ 
between mesothelin positive and negative cells represent for anti-mesothelin mAb-spdp-
nRTA chemical IT a good preliminary proof of efficacy for further in vivo experiments 
using mouse models of malignant mesothelioma, pancreatic, ovarian and lung 
adenocarcinoma. 
Abovementioned data are even more encouraging once considered that there are many 
further perspectives for future developments regarding the use of our ―home-made‖ 
anti-mesothelin mAb. 
First of all, the sequence identification of the variable regions (VH and VL) will allow 
us to proceed with the synthesis of scFv antibody fragments showing more reduced 
dimensions; so we could have mesothelin-specific tool and a molecule suitable for 
further genetic engineering. The obtained scFv will be tested on mesothelin-positive 
cells to prove its functionality and specificity. When compared to their whole molecule 
counterparts such smaller-size proteins have a lower plasma half life because scFvs are 
more rapidly cleared from the blood by renal filtration. On contrary these small proteins 
have better penetration rates in the tumor mass (known to have an high interstitial 
pressure) to improve the total killing of tumor cells. Paradoxically the lower affinity of 
single chain antibodies, in respect to the whole molecule counterpart, can itself lead to a 
better penetration into the core of tumor masses, overcoming the so called ―antigen site 
barrier‖ that otherwise leads to an early and massive binding of highly affine antibodies 
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to their cognate ligands in the outer layers of tumor mass, preventing a deeper 
penetration. All abovementioned properties lead to an improvement in tumor-blood 
ratio concentrations for scFv reagents. This property is particularly favourable for 
radioimmunoimaging/therapeutical applications once reagents are sequentially 
administered; pre-targeted single chain antibodies, either monomeric or multimeric with 
unique or different specificity, can be administered in high doses, in order to reach the 
highest concentration inside the tumor, with few side effects. In the following loading 
phase cytotoxic moiety can be rapidly and efficiently directed to the pretargeted site. 
This strategy leads to an improvement of the therapeutic index once compared to the 
administration of radioimmunoconjugates as single molecules, because of fewer side 
effects for the same dose of radioactivity.  
We than will produce engineered fusion protein (scFv anti-mesothelin – PE40) and the 
powerful and specific cytotoxic action against mesothelin-positive cells will be 
measured. Fusion ITs are more stable, easier to produce in large amount and have 
highly reproducible chemical properties due to the constant 1:1 antibody:toxin ratio. 
One possible problem of the IT is related to the immunogenicity of both scFv and toxic 
moiety due to the well-known HAMA and HATA (anti-toxin antibody) responses. 
Possible measures to overcome this problem will include humanization of scFv. 
Another interesting field of application of our ―home-made‖ anti-mesothelin antibodies 
is represented by antibody functionalized nanoparticles for tumor targeting (AFNaTT). 
Nanoparticles are in fact of great interest for use in biomedicine as imaging tools, 
photherapy and heat therapy agents and also for gene carrying; due to their very low 
dimension, in the ―mesoscopic‖ size range of about 10- to 100-nm diameter, these 
structures show some interesting characteristics: optimal surface areas for conjugation 
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of carriers molecules such as antibody or their scFv fragment, a volume that allow their 
loading with high amounts of trackers agents (i.e. optical, radioisotopic or magnetic) but 
at the same time a dimension consistent to an efficient blood stream carriage and a 
substantial extravasation at the tumor site. 
Gold NP are also very interesting for their chemical inertness; they are resistant to 
oxidative conditions which permits a direct linking of different organic/biological 
molecules via gold-sulphur bond or electrostatic attraction. Gold itself shows a 
biological inertness and no long-term toxicity, as proved by its historical use in different 
clinical setting from dental implantology to the management of the rheumathoid 
arthritis. 
Gold NP shows optical properties that can be enhanced by linking at their surface SERS 
(surface enhanced Raman scattering) molecules; SERS amplifies the Raman scattering 
of about 1014- to 1015-fold, allowing detection and identification of an even limited 
number of nanoparticles. Optimized Raman signal has to date increasing applications in 
tumor imaging, taking advantage of some peculiar physical properties. Raman peaks are 
in fact narrower in respect to conventional fluorescence ones, allowing an easier signal 
detection in complex systems such as tissues having many potentially interferent 
autofluorescence signals (i.e. heme groups, flavonoids etc.). 
Finally, there are many further perspectives for future developments regarding the use 
of our anti-mesothelin mAb as its biotechnological derivates. By actually our on-going 
collaborations in the field of cancer diagnosis and therapy we will can: 
_ to use T cell chimeric receptors containing anti-mesothelin scFv as their extracellular 
recognition elements will can redirect the specificity of T cells in an MHC-independent 
manner (T-body); 
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_ to evaluate the apoptotic effect of fusion protein scFv anti-mesothelin-TNFα on 
mesothelin positive tumor cells; 
_ to evaluate the ability of scFv anti-mesothelin-DOTA-Radionuclide conjugate in 
tumor imaging and therapeutical applications. The goal of this project could be to 
produce in GMP conditions Ab and scFv and to start with phase 0 clinical trials after a 
preclinical setting in mouse models; 
_ to develop bispecific scFv, anti-mesothelin and anti-CD16, which are able to redirect 
NK cells at the tumor site. It is known that NK cells are less prone to be influenced by 
immunosuppressive tumor environment; 
_ to evaluate the efficacy of pre-targeting methods based on bispecific Ab anti-
mesothelin and anti-hapten, created using the Dock and Lock method.  
After a ―pre-loading‖ of specific antibody at tumor site (via venous systemic injection), 
a radiolabeled hapten will be injected in order to be captured, in the same site, from the 
―resident‖ specific Ab. 
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